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Thesis Abstract 
Multimodal imaging probes can provide diagnostic information 
combining different imaging modalities. Nanoparticles (NPs) can 
contain two or more imaging tracers that allow several diagnostic 
techniques to be used simultaneously. In this thesis, a complex 
coacervation process to produce core-shell completely biocompatible 
polymeric nanoparticles (HyCoS) for multimodal imaging 
applications is described. Innovations on the traditional coacervation 
process are found in the control of the reaction temperature, allowing 
a speeding up of the reaction itself, and the production of a double-
crosslinked system to improve the stability of the nanostructures in 
the presence of a clinical relevant contrast agent for MRI (Gd-
DTPA). Through the control of the crosslinking behavior, an 
increase up to 6 times of the relaxometric properties of the Gd-
DTPAis achieved. Furthermore, HyCoS can be loaded with a high 
amount of dye such as ATTO 633 or conjugated with a model dye 
such as FITC for in vivo optical imaging. The results show stable 
core-shell polymeric nanoparticles that can be used both for MRI and 
for optical applications allowing detection free from harmful 
radiation. Additionally, preliminary results about the possibility to 
trigger the release of a drug through a pH effect are reported. 
Furthermore, NPs combined with peptides, allow an efficient in vivo 
targeting useful to improve drug delivery and clinical outcome. We 
report the in vivo targeting of aggressive A20 murine B-cell 
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lymphoma by idiotype-specific peptide pA20-36 using fluorescence 
molecular tomographic (FMT) imaging in xenograft mouse models 
of lymphoma A20, through VivoTag probe, an amine-reactive near-
infrared fluorochrome. In the end, core-shell polymeric nanovector 
with improved relaxometric properties for simultaneous PET/MRI 
acquisitions. and 
18
F-FDG is used as tracer for PET. A protocol for 
sorption of 
18
F-FDG into the nanoparticles is studied and designed to 
be integrated downstream the production of the tracer.  
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Introduction 
Therapy and Multimodal Imaging  
Nowadays, the possibility to combine a drug for a specific disease 
with one or more tracers for their use in simultaneous diagnostic 
techniques is the new frontier of the modern medicine
1
. 
Pharmaceutical companies have striven to produce diagnostic 
compounds with higher efficacies and improved safety profiles. 
Traditionally, drugs have low molecular active compounds which are 
often the result of engineering of a natural product
2
. They can be 
classified according to the active principle, the mechanism of action, 
their use and the type of administration
3
 
4
 
5
 During a therapy it is 
crucial to monitor the therapeutic effect through the use of diagnostic 
technologies
6
 furthermore,  the possibility to integrate different 
imaging modalities contributes to an earlier and accurate diagnosis. 
The‬ term‬ “multimodal‬ imaging”‬ is‬ referred‬ to‬ the‬ integration‬ of‬
diagnostic technologies based on different physical principles for the 
acquisition of complementary information
7, 8
. Currently, the 
modalities available for imaging include optical imaging, magnetic 
resonance imaging (MRI), nuclear imaging, computer tomography 
(CT), and ultrasound (US)
9
. These technologies can acquire 
simultaneously or consequently the different information
10
. The 
asynchronous post-processing acquisition presents various problems, 
all based on the different position that the patients acquire during the 
different exams in the instruments. For this reason, the worldwide 
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companies are working to integrate different diagnostic techniques 
based on different physical principles in a single diagnostic 
instrument
11
. This allows to overcome the various limitations as the 
partial volume effects. In the last decade, instruments such as 
PET/MRI and Optic/PET machines have answered to this request 
allowing the simultaneous acquisition of structural, functional and 
metabolic information.  
Diagnostic Techniques 
Among the different diagnostic techniques, the most commonly used 
for the detection of tumor and neurodegenerative diseases is the 
MRI. 
Magnetic Resonance Imaging (MRI) and Contrast Agents 
(CAs) 
Magnetic Resonance Imaging 
12
 is one of the most important non 
invasive imaging modalities in clinical diagnostics and research, its 
characteristic is to use not ionizing rays. This technique has the 
ability to image tissues with high resolutions in three dimensions. 
More important however is the unique ability of MRI to obtain 
information both on anatomy and on a wide range of physiological 
parameters within a single examination, unsurpassed by other 
techniques
13
 
14
. MRI allows obtaining images by measuring the RF 
signals originating from the magnetic moments of lipid and mainly 
water protons in living tissues. The use of water as a probe molecule 
has many advantages. First of all, the proton has the highest 
10 
 
sensitivity among biologically relevant nuclei, and water is present in 
high concentrations in all tissues. The magnetic properties of water 
are sensitive to the local microstructure and composition of 
biological tissues. However, sometimes insufficient contrast is 
observed and so the use of contrast agents (CAs) is of great 
assistance in many applications of MRI or of other diagnostic 
techniques
15
. MRI contrast agents are used to improve the visibility 
of internal body structures in magnetic resonance imaging (MRI), 
they can be divided in paramagnetic, superparamagnetic, and 
ferromagnetic compounds
16
. A number of such substances have been 
developed and research continues in order to find more selective 
contrast media that will allow a better delineation of diseases, thus 
helping radiologists to make a more precise diagnosis 
17
. MRI 
technique exploits the minute imbalance in the number of spin-up 
and spin-down protons when they placed in a strong magnetic field, 
which produces a tiny net magnetization in thermal equilibrium. The 
equilibrium can be disturbed by radiating the protons with an 
external resonant radio-frequency (RF) electromagnetic field leaving 
the system in an excited state. When the RF field is turned off the 
system relaxes back to thermal equilibrium with a process that is 
known as relaxation. There are two different relaxation processes 
spin-lattice or longitudinal relaxation (T1) while the second is spin-
spin or transverse relaxation (T2). The transverse relaxation process 
may be accelerated by microscopic and macroscopic magnetic field 
11 
 
inhomogeneities in which case the latter relaxation process is 
referred to as T2*. Most of the contrast agents generate contrast by 
changing the T1 and T2. Relaxivity (r1 and r2) is a parameter that is 
inversely proportional to the relaxation times and it characterizes the 
properties of a MRI contrast agent. Relaxivities r1 and r2 are 
dependent on the magnetic field strength. Generally, r1 decreases at 
higher field strength while r2 stays constant or increases
15, 18
. The 
ratio between r2 and  r1 determines whether a contrast agent is suitable 
for contrast enhanced T1-weighted imaging or whether it can be used 
for contrast enhanced T2- and T2*-weighted imaging. However, the 
MRI contrast agents can be classified into two groups: CAs which 
increase the transverse relaxation rate (1/T2) and those that increase 
the longitudinal relaxation rate (1/T1).  
T1 contrast agents are prevalently paramagnetic contrast agents, they 
are used to enhance MR images and to detect hypervascularity and 
diseases. They have their strongest effect in T1 weighted imaging 
because they predominantly alter the T1 relaxation time in the tissues 
in which they have accumulated. MRI imaging is based on the signal 
derived from the behavior of water protons, their relaxation is 
affected by the surrounding tissues and, in presence of a 
paramagnetic contrast agent this parameter enhances. Paramagnetic 
Gadolinium (Gd) based on contrast agents are examples of T1 
agents
13
. Gadolinium (Gd) is a paramagnetic ion with seven unpaired 
electrons. It disturbs the relaxation of nearby water protons, causing 
12 
 
decreases of both T1 and T2 relaxation times being stronger with the 
concentrations used in clinical practice. 
Free iones of Gadolinium (Gd) are toxic in vivo (lethal dose for 50 % 
of the population (LD50) for GdCl3 in mice 100 – 200 mg/kg) 
19
 but 
its binding to a chelate complex makes it chemically inert. After 
chelation, the rate of renal excretion of the Gd complex is increased 
approximately 550-fold compared with pre-chelation values
12
. For all 
types of contrast agents exists a precise dose to administrate in 
relation to the weight of the patient and other details as the age or the 
presence of a specific desease
20
. 
The Gd chelates are approved for clinical use in the international 
market. For clinical use, the recommended dose is 0,1 mmol/Kg. The 
values of T1  and T2 can be measured or by region of interest (ROI) 
through MRI image or by relaxometer using two different types of 
applications that are called saturation recovery (SR) or inversion 
recovery (IR)
21
. Commonly non specific extracellular gadolinium 
chelates include
21
: Magnevist, Dotarem, ProHance, Gadovist, 
MultiHance, Omniscan, OptiMARK. 
There are many advantages using contrast agents as include better 
lesion enhancement, delineation and detectability of Central Nervous 
System (CNS) but there are also some limitations and drawbacks. 
Fist limitation is toxicity. Free ion Gd is acutely toxic owing to its 
tendency to precipitate and be deposited in liver, lymph nodes, and 
bones. It may also obstruct calcium-ion passage through muscle 
13 
 
cells, and block the flow of calcium in bone epiphyses and nerve 
tissue cells, causing the arrest of neuromuscular transmission. A 
primary factor contributing to the toxicity of Gd complexes is its 
capability to replace some endogenous metals, especially Zinc, this 
phenomenon is called trans-metallation. Another important 
parameter which governs toxicity is the stability of the complex. The 
tolerance of Gd chelates is excellent at both standard and higher 
doses, with no clinically relevant difference among these agents, 
same adverse events are observed with an incidence of less than 2%, 
with most being mild and transient. The frequency of single adverse 
events is approximately 1% or less of all patients. The most 
frequently reported adverse events are nausea, headache and 
vomiting; they are not severe and do not require specific treatment
20
. 
Anaphylactic reactions, involving respiratory, cardiovascular, 
cutaneous, gastrointestinal and/or genitourinary manifestations have 
been reported with a prevalence of between 1/100.000 to 
1/500.000
20
. Gd chelates have not been approved for use in pregnant 
women, because of the lack of information on potentially harmful 
effects on the embryo and fetus and on the clearance rate of Gd 
chelates from the amniotic fluid by the mother
22
. There are other 
types of risks as the renal insufficiency, one of the major risk factor 
using Gadolinium is Nephrogenic System Fibrosis (NFS) 
23
 
24
. NSF 
was observed for the first time in 1997 and it presents with rapidly 
progressive skin thickening, tethering and hyperpigmentation, 
14 
 
principally involving the extremities. It is a systemic disease that is 
associated with exposure to gadolinium-based MRI contrast in 
patients with compromised renal function. For those afflicted, this 
disorder has caused indescribable suffering, permanent disability and 
increased mortality
25
. Furthermore, recent concerns about the 
deposition of clinical relevant Gd-based Contrast Agents, linear and 
macrocyclic one are reported by Robert McDonald on 
neuroradiology
26
 and other publications
27
 
28
. Moreover, the recent 
opinion of the FDA suggests the limiting the Gadolinium-based CAs 
use to clinical circumstances in which the additional information 
provided by the contrast is necessary. On the same course of action, a 
general review also has summarized the literature on gadolinium-
based contrast agents 
29
 and so the importance to protect the Gd, both 
linear and macrocyclic, and overcome the low specificity of the CAs. 
Furthermore, for linear and macrocyclic both, relaxivity is well 
below the required theoretical limits and the boost of the signal is 
still a challenge. Furthermore, in many cases, it is not the tissues 
under investigation being imaged, but the tracking agent. This can 
result in false positive results. 
Positron Emission Tomography (PET) and 
Radiopharmaceuticals 
The Positron Emission Tomography (PET) 
30
 is one of the nuclear 
medicine techniques, which allows the in vivo measure of the local 
concentration of radiopharmaceuticals which emits positrons and the 
15 
 
obtainment of functional images . The sensitivity of a PET scan is 
about 10-11-10-12 mol/L. Usually, some millions of cells that 
include the radioactive probe are enough to discriminate a particular 
phenomenon. In PET, radioisotopes emitting positrons are used 
following a β- decay. These, after traveling a short distance, 
annihilate with an electron of the surrounding medium. As a result, 
of the annihilation process, they are issued simultaneously two γ-
ray energy of 511keV. The two photons are emitted simultaneously 
along the same direction, but in the opposite direction, and their 
flight direction is defined using a number of detectors in time 
coincidence places around the patient. The angle of emission of a γ 
ray respect to the other is about 180°, for which it can be assumed 
that the two rays traveling on the same flight line. The aim of a PET 
survey is to calculate the measure of the activity of local density ρ 
(x, y, z) of the radioisotope, such information can be obtained from 
linear integrals. The instrumentation must, therefore, be capable of 
measuring the flight lines of a pair of annihilation photons. The γ-
rays are then detected through a system of temporal coincidence 
between the detectors which classifies the spokes as belonging to the 
same annihilation event. It is measured so the line of response (LOR) 
and software uses this information to obtain the concentration of the 
radioisotope. Among the disadvantages of PET, there is the toxicity 
of its tracers, the low resolution and the possibility of obtaining 
16 
 
functional information without a structural support. Furthermore, in 
patients with altered chemical balance, there is a limitation in the 
detection of tumors smaller than 1 cm. The term 
“radiopharmaceutical” is defined as any medicinal product which 
contains one or more radionuclides (radioactive nuclei). Besides that 
according to their chemical structure, the localization mechanism and 
to the therapeutic action, radiopharmaceuticals are usually classified 
according to the type of "positive" or "negative" display that they can 
produce in the specific diagnostic application33. In particular, a 
positive indicator radiopharmaceutical accumulates electively where 
there is the disease process, highlighting directly the area of the 
specific metabolic alteration; on the contrary, a radiopharmaceutical 
negative indicator accumulates in the normal parenchyma and 
functioning of an organ and, therefore, the disease is highlighted as a 
defect of uptake process. If the radiopharmaceutical is able to bind 
specifically to cancer cells, it also becomes not only therapeutic and 
diagnostic. For the choice of a radiopharmaceutical is important to 
take into consideration that it must be possible to replace an atom of 
common biological molecules without significantly vary the 
metabolic and/or behavior must have a half-life compatible with the 
biological half life of the carrier molecule and with the time required 
to marking. For these reasons, the most widely used radionuclide for 
PET studies is the Fluorodeoxyglucose (
18
F-FDG). 
18
F-FDG is a 
glucose analog to which a oxydrile group is substituted by a 
17 
 
radioactive Fluorine (F) and its decay time is about 109 minutes
30
. 
The radioactive fluorine is taken up by cells that use large amounts 
of glucose, first of all the cells of the brain, kidney, heart and cancer 
cells. In particular, the cancer cells have an intense glycolytic activity 
and therefore accumulate greater amounts of the drug. The molecule 
is phosphorylated at position 6, so that they can not escape from the 
cell. In the form of FDG-6-phosphate it can not be catabolized in the 
glycolytic pathway and remains in this radioactive form visible to the 
PET, before its decay. the use of FDG, therefore, is an excellent 
method to assess the biodistribution of glucose and its 
phosphorylation in several districts of the organism. It is an 
extremely precise and clean instrument, also following the decay 
there is no cellular accumulation of biomolecules. This 
radiopharmaceutical is used to diagnose and/or evaluate the 
progression do monitor the effectiveness of treatment for a tumor: 
the Hodgkin and no lymphoma and lung cancer. Its use has also been 
approved for the diagnosis of Alzheimer's disease. Radioactive 
fluorine atoms on other molecules can from life to other 
radiopharmaceuticals used in clinical settings as 
18
F-DOPA and 
18
F-
ET used above all for cerebral tumor detection; 
18
F-MISO for the 
detection of cellular hypoxia or 
18
F-FLT in order to characterize the 
uncontrolled cellular proliferation.  
18 
 
Simultaneous PET/MRI 
Both just described diagnostic techniques, MRI and PET, can be 
combined in a unique machine to provide complementary anatomic, 
physiologic, metabolic and functional information. Moreover, the 
simultaneous acquisition immediately brings to mind the possibility 
of improving the performance and information content of one 
instrument using the information obtained from another instrument: 
the accuracy of the PET estimates might be improved by including 
the MRI information as the structural framework underlying the 
distribution of the PET signal
34
. Reciprocally, the strength of PET to 
provide absolute quantitative information might help validate several 
MRI techniques in vivo. Simultaneous PET/MRI offers the unique 
option of carefully addressing these issues through accurate MRI-
based motion and Partial Volume Effects (PVE) correction
35
. 
Furthermore, PET/MRI is a useful tool for developing a normal 
control database based on FDG-PET
36
 since they are yet coregistered 
and no alignment algorithm is required, in fact T1-weighted MR 
images are solid and strong and provide a great morphologic 
improvement in PET analysis
37
 otherwise there are several concerns 
about the attenuation correction and segmentation. Hence the birth of 
an integrated system PET/MRI
38, 39
, which is still little used because 
its use is linked to the simultaneous administration of the means of 
magnetic resonance contrast and radiopharmaceutical for PET, 
increasing side effects for the patients. 
19 
 
Optical Imaging and Fluorescence Tomography (FMT) 
Optical Imaging is a diagnostic technique that uses light at different 
wavelengths in order to detect cellular and molecular function in the 
living body
40
. The used wavelengths are in a range that comes from 
ultraviolet to infrared. The contrast of the images derived from the 
use of reporter genes, endogenous molecules with optical signatures 
and exogenous agents. The Optical Imaging includes different types 
of techniques, which use a different kind of light in order to reach the 
final objective such as Bioluminescent imaging (BLI) and 
Fluorescence Imaging. In particular, Fluorescence imaging uses 
endogenous or exogenous molecules or materials that emit light 
when activated by an external light source as a laser
41
. A light at a 
specific wavelength excites a target molecule which fluoresces by 
releasing longer-wavelength and lower-energy light
42
. This type of 
diagnostic technique is able to localize and measure genes, proteins; 
to evaluate the cell trafficking, to tag the superficial structures, to 
detect lesions, to monitor tumor growing and other pathophysiologic 
processes. In clinical practice, the fluorescence imaging is entering 
initial clinical testing in areas such as breast imaging and 
endoscopy
43
. Respect to other diagnostic techniques the optical one 
is able to provide real-time information in order to support surgeon 
during surgery and has exquisite sensitivity and resolution
44
. 
However, it has a lack of mainstream clinical instrumentation, it has 
different limitations related to absorption and scatter and 
furthermore, it is not able to penetrate deeper than few centimeters.  
20 
 
In the last years, this technique has been very used to study small-
animal models, providing unique insights into disease pathogenesis, 
drug development and the effects of therapy. Future development of 
this technique will be the design of new probes and nanomaterials 
which can detect lesions a few centimeters deep in tissue; the 
development of the probes that can be used for multimodal 
applications or which can release a specific enzyme or defined 
target
44, 45
. 
Theranostic 
The‬term‬“theranostics”‬ is defined as the possibility of exploiting a 
single agent for diagnostic and therapeutic purposes simultaneously. 
Administering a theranostic agent gave the possibility of being able 
to combine different contrast agents or radiopharmaceuticals for 
diagnostic technologies developed over time with the release of 
specific drugs or supplements for different types of diseases, tumor 
lesions, tissue degenerations, neurodegenerative pathologies as 
Alzheimer`s disease and inflammations. Nowadays, the difficult to 
project the design of a theranostic nanovector (TPNs) is to combine 
the use of biocompatible materials to exploit their properties and 
peculiarities in order to achieve structures that can increase the 
efficiency of diagnosis, increase the therapeutic effects and at the 
same time control that the two mechanisms occur at different times 
of action. Indeed, the clearance of a vector in fact is another key 
factor, it must be fast enough to allow the elimination of a diagnostic 
21 
 
agent such as a contrast medium or a radiopharmaceutical from the 
blood stream but sufficiently slow to allow the controlled release of 
a drug, a supplement or a therapeutic substance that we want to 
encapsulate in. The development of effective TNPs will require 
some give and take between imaging sensitivity, the accuracy of 
targeting, and controlled drug release. Via a host of materials, many 
pathways are being explored to reach these goals.  
In the therapeutic area, there are many different methods for 
administering a therapeutic agent, such as administration through the 
oral cavity, through injection in different sites of action, through the 
nasal mucosa, through the use of surgically implantable devices or 
through drug delivery by micro and nanocarriers. Controlled Drug 
Delivery technology represents one of the most rapidly advancing 
areas that offer numerous advantages compared to conventional 
dosage forms including improved efficacy and reduced toxicity
46
. In 
addition, the diagnostic field aims to reach an even more high 
resolution images in order to have an early detection of different 
kinds of diseases.   
 
Nanomedicine and Nanostructures 
The introduction of nanotechnology has led in the course of time to 
the development of a large number of medical applications including 
the formulation of new systems for the controlled delivery of the 
drugs and the development of new nanometric structures that can be 
22 
 
used both in diagnostic and in therapeutic applications (TNPs)
47
. The 
unusual properties of nanoparticles can be exploited to modify the 
kinetics of a drug carrier for the transport of hydrophilic and 
hydrophobic substances, to cross biological barriers as blood brain 
barrier (BBB) and to highlight some diseases as tumor 
microenvironment or neurodegenerative diseases. The difference 
between natural and engineered particles is deep. While the first are 
generally not very reactive, biodegradable and tend to interact with 
each other to form clusters poorly reactive, the others are, thanks to 
their high surface area which exposes the surface most of the atoms 
that compose them, highly reactive, much less available aggregation 
and persist in external ambient thanks to their poor biodegradability. 
The use of engineered materials and the production through the 
different production methods allow to obtain particles with different 
surface charge, size, shape and texture that can be used for different 
types of applications. The nanoparticles can be classified for 
morphology and architecture into two categories: the nanospheres 
and nanocapsules. The nanospheres have in fact a polymer matrix 
inside the particle itself while the nanocapsules have a liquid core 
surrounded by an outer polymeric membrane
48
. In particular, the 
latter allows a high encapsulation power of active ingredients and 
substances as drugs
49
. The particles are differentiated by type of 
material, for surface charge, size, shape and method of preparation 
with which they were obtained.  
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The main production methods are nanoprecipitation, Emulsion-
Diffusion, Double Emulsification, Polymer-Coating, Layer by Layer 
and Emulsion-Coacervation
48
. Between them the emulsion-
coacervation method is the less explored for theranostic and 
multimodal imaging applications although it appears to be a method 
of producing highly productive. The Emulsion-Coacervation is a 
chemical phenomenon during which a homogeneous aqueous 
solution of charged macromolecules, undergoes liquid-liquid phase 
separation, giving rise to a polyelectrolyte-rich dense phase and to a 
supernatant which remains in equilibrium with the coacervate phase. 
These two liquid phases are immiscible and hence, are incompatible. 
It is important to highlight the coacervation from the precipitation 
process, in the last case, in fact, there is not a liquid-liquid phase 
separation as in the first case but a solid-liquid one. The factors that 
can influence the coacervation process are many and very different 
from each other: Ionic Strenght (Salt concentration); The 
polyacid/polybase ratio; Total polymer concentration; pH; Molecular 
weight of polyelectrolytes; Temperature. The main mechanisms of 
coacervation process are the desolvation of polymer, the repulsion 
between two different polymers that are solved in the same solvent, 
the interactions between a polymer poly-ions with a polymer with an 
opposite charge and solvation, or dissolution, which is the process of 
attraction and association of molecules of a solvent with molecules 
or ions of a solute.  
24 
 
There are various types of coacervation in relation to the production 
process used, they can be divided in: Simple coacervation (Variation 
of temperature, Addition of salt, Variation of pH, Addition of a non-
Solvent, Addition of Incompatible Polymer) and Complex 
Coacervation.  
In simple coacervation the addition of salt or of a non-solvent or of 
an incompatible polymer or the variation of same conditions 
promotes the coacervation. Indeed, complex coacervation of 
polyelectrolytes can be achieved through electrostatic interaction 
with oppositely charged proteins or polymers. The charges on the 
polyelectrolytes must be sufficiently large to cause significant 
electrostatic interactions, but not so large to cause precipitation.  
Coacervation has been used in processed food, cosmetics, paper and 
textiles, and in the pharmaceutical and food industries as 
microencapsulates for drugs and flavours
50
. Nanoparticles produced 
by the method of emulsion-coacervation are based on the creation of 
a template emulsion on which goes to deposit the coacervate 
material. In the first chapter of this thesis work it will be described 
some different applications of nanoparticles obtained by 
coacervation process and if they are in vivo tested in order to 
understand the limitations or drawback, to study the biodistribution, 
the toxicity and the clearance of the NPs themselves
51
 
52,53
.  
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Aim, major findings and perspectives 
The aim of this thesis work is the design and the development of 
theranostic multimodal NPs which can be used for simultaneous 
MRI/PET and Optical Imaging applications. Any efforts will be 
given to the design of the Nanoparticles to obtain an architecture able 
to boost the MRI signal over the typical relaxivity of clinical relevant 
contrast agents. At the same time the nanovector with improved 
relaxometric properties should be able to deliver a radiotracer and/or 
an optical tracer or even a drug. A such advanced probe would avoid 
the administration of a cocktail of different tracers for Multimodal 
Imaging applications. Furthermore, an active targeting of the 
nanostructures will be tested in order to make it specific for a disease 
or an organ for both therapeutically and diagnostic applications. In 
particular, in the second chapter, a specific application for a 
lymphoma B-cell is described. The selected peptides are described in 
the literature to induce the reduction of tumor mass after different 
administration
54
. In the first chapter, a variation of the classic 
coacervation. Investigations report the effect of the temperature and 
double crosslinking to improve the stability in presence of contrast 
agents. The Chitosan and HA are chosen for their biocompatibility, 
the different degradation times and the opposite charge of each. 
Moreover, HA is selected for its hydrophilicity as the coacervate 
polymer to create the external shell of the nanoparticle. The choice of 
an HA with a higher molecular weight (if compared to a lower 
26 
 
molecular weight of Chitosan) allows the complete coating of 
nanodroplets template of Chitosan. The diagnostic field is one of the 
less explored for this production process due to the difficulty of 
reaching very small dimension and of integrating different kinds of 
tracers for multimodal applications. The process is designed to be 
used in industrial context for its high productivity. In vivo results are 
reported for MRI and Optical Imaging application while for 
simultaneous PET/MRI scan in vitro tests are reported.  
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CHAPTER 1 
1 Hybrid Core-Shell (HyCoS) Nanoparticles 
Produced by Complex Coacervation for 
Multimodal Applications 
 
 
Figure 1-1: Graphical representation: Ternary system Ch-CH3COOH-H2O. The red 
area represents the miscibility range of Chitosan into an Acetic Acid solution. 
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1.1 Introduction 
Coacervation is defined as a spontaneous formation of a dense liquid 
phase from a macromolecular solution of poor solvent affinity. The 
Emulsion-Coacervation processes are considered a scalable, 
reproducible and relatively low-cost approaches; furthermore, they 
provide main advantages in terms of high payload (up to 99%) and 
controlled release properties.  The coacervation process is primary 
used for the production of micrometric morphologies but thanks to 
the optimization of the process parameters different authors have 
presented some applications of nanoparticles obtained by 
coacervation process
5,7
. Furthermore, nanocapsules by coacervation 
are used in many different applications as drug delivery system in 
medicine and in food or cosmetic industries. In medicine, they are 
used both in therapeutic and in diagnostic applications. The ability of 
nanoparticles to manipulate the molecules and their structures has 
revolutionized the conventional drug delivery system
1
. Among 
materials that are used for nanoparticles production by coacervation 
there are many polymeric materials as PEG, PLLA, HA, Chitosan 
and other natural components as gum arabic, jelly or legumin
2
. 
Chitosan nanoparticles are usually applied because of their 
biodegradability, biocompatibility, better stability, low toxicity, 
simple and mild processing conditions and furthermore they offer a 
valuable tool to novel drug delivery systems in the present scenario
3
. 
Chitosan in a work by Lee et al. was applied for the production of 
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nanoparticles encapsulating siRNA
4
. Arnedo et al. 
5
 produced by 
coacervation albumin nanoparticles for drug delivery for antisense 
oligonucleotides
5
. The same type of nanoparticles was used by Das 
et al. to encapsulate Aspirin, a common anti-inflammatory and anti-
platelet agent widely used for various conditions
6
. Other application 
of Coacervate nanoparticles came by Gallarate et al in 2010
1
, where 
solid lipid nanoparticles for the encapsulation of peptides
1
 were 
described. Differently from the simple coacervation, previously 
described, following different cases study of complex coacervation 
exploiting the combination of more materials as the HA and the 
Chitosan will be presented 
4, 5, 7
. This method is called Complex 
Coacervation because is based on the phase separation of more than 
one encapsulation agent. In 2000 Mao et al. 
8
 obtained Chitosan-
DNA nanoparticles (GNPs) by Complex Coacervation. The size of 
particles was optimized to 100-250 nm, with a composition of 35.6% 
and 64.4% by weight of DNA and Chitosan. The particles 
encapsulated plasmid DNA (GNPs) from nuclease degradation. 
Various types of crosslinkers were used to improve the 
physiochemical properties of GNPs, including aldehydes, genipin, 
carbodiimide/N-hydroxysuccinimide, and transglutaminase
8
. The 
GNPs, thanks to their biocompatibility and biodegradability, were 
chosen for the ocular drug delivery In 2014 Zhao et al. 
9
 created 
optimal preparation conditions of Newcastle disease virus (NDV) F 
gene deoxyribonucleic acid (DNA) vaccine encapsulated in Chitosan 
37 
 
nanoparticles (pFNDV-CS-NPs) through a Complex Coacervation 
process. In the application of the nanotechnology to the medical field 
(nanomedicine), optimization of the size is one of the most important 
parameters to perform an efficient delivery and overcome biological 
barriers reaching a specific organ or a tumor mass
10
. The production 
by complex coacervation of nanoparticles to be applied in the 
diagnostic field has not been fully explored/investigated because of 
the complexity to control all the process parameters simultaneously 
considering the concurrent presence of more than one active 
compounds. However, the exploitation of this approach could bring 
to the combination of different contrast agents, drugs and polymers 
before being processed or the use of not completely biocompatible 
materials, solving typically unstable behavior related to the 
nanoparticles in the diagnostic applications
7
. In 2008 Huang et al. 
11
 
have presented a system in which polyelectrolytes complex (PECs) 
of 300nm in diameter were formed by a complex Chitosan 
Coacervation with dextran sulphate and presented nanoparticles 
having colloidal stability in simulated serum. The Gd was 
incorporated through two different procedures: first of all the DTPA 
with Gd chelate was grafted into Chitosan before the complexation 
with dextran sulphate. Then, the Gd was also incorporated into 
PECs, mixing them with GdCl3, resulting in ionic trapping of Gd 
ions within the PECs. Another application of nanoparticles obtained 
by Coacervation process in MRI detection was discussed by 
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Saboktakin et al. in 2010, who used Chitosan–dextran sulphate (DS) 
nanoparticles coated with iron oxide as drug transporters, detectable 
using the magnetic resonance imaging (MRI) technique
12
. Studying 
various parameters such as pH, the concentration of the polymers, 
the percentage of crosslinkers, the reaction temperature and the 
volume of the different phases, Liu et al.
7
 have shown how to 
develop a stable micro-system in an aqueous environment in the 
presence of an encapsulated chelate contrast agent too. The 
possibility to design a core-shell architecture thanks to coacervation 
process makes the vectors useful for theranostic or multimodal 
diagnostic applications combining different tracers or drugs. On the 
basis of the previously reported results, the application of the 
complex coacervation based processes to the production of 
nanoparticles forAdvanced Multimodal Imaging applications seems 
to be very promising. Indeed, despite the recent advances in the 
single diagnostic techniques
13
, the study on diagnostic technology is 
still continuous, and it focuses on the disparity of diseases and the 
type of information provided by the single techniques
14
. In this 
scenario fits the Multimodal Imaging because it can combine two or 
more techniques based on different physical principles allowing the 
integration of functional information to structural ones
15
, overcome 
limitations of the single diagnostic techniques and optimize therapies 
leading‬ to‬ a‬ “personalized‬ medicine”16. Among the multimodal 
applications, Nuclear Magnetic Resonance-Optical dual imaging 
39 
 
modality has the principle advantage to be completely free from 
ionization rays while anatomical and molecular, physiological or 
metabolic information are provided. Magnetic Resonance Imaging 
(MRI) is characterized by a relatively high spatial resolution, 
relatively no tissue penetrating limits but also it has a low sensitivity, 
high cost and long imaging time. 
Differently from MRI, Optical Imaging has a higher sensitivity; it is 
a multicolor Imaging which allows visualizing target biological 
molecules (peptides, drugs, etc.) but it presents a low spatial 
resolution and a poor tissue penetration. Among different optical 
techniques, the Fluorescence Molecular Tomography (FMT) 
produces quantified 3D reconstructions of fluorescence activation or 
concentration. In this framework, their combination can provide 
information not available typically by applying the single 
methodologies and allows to distinguish finely in different tissues 
within the body
17
. The introduction of nanotechnology has led to the 
development of many medical products including the formulation of 
new probes that can be used for multimodal applications
18-22
. Among 
them, nanovectors can potentially provide early diagnosis and 
monitoring of therapeutic response 
23, 24
 and play a significant role in 
the dawning era of personalized medicine
25-27
. Nowadays, although 
many efforts are made in the development of instrumentations for 
Multimodal Imaging, this field still lacks biocompatible, 
biodegradable and Food and Drug Administration (FDA) approved 
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probes
28
. In literature, different studies about dual imaging MRI and 
Optical Imaging are reported 
21, 29, 30
. In 2009, Xie et al. 
31
 produced 
Iron oxide nanoparticles (IONPs) for PET/NIRF/MRI applications 
labeled with Cy5.5 dye and 
64
Cu-DOTA chelates. In the same period, 
Chen et al. 
32
 presented the IONPs nanoparticles coated with a 
PEGylated amphiphilic triblock copolymer conjugated with a near-
infrared fluorescent (NIRF) dye IR-Dye800 and with a 
64
Cu-DOTA 
chelates. In 2010, Nam et al. 
33
 reported tumor targeting 
nanoparticles for optical/MRI dual imaging based on self-assembled 
Glycol Chitosan (GC) which was chemically modified with‬ 5β-
Cholanic Acid (CA). For optical imaging, (GC-CA) was used as a 
chelate for Gd(III) and Cy5.5 was conjugated. Tan et al. 
34
 in 2011, 
presented a multimodal imaging system by co-encapsulating 
superparamagnetic iron oxides (IOs) and Quantum Dots (QDs) in 
Poly(lactic acid)-d-αtocopheryl‬ polyethylene‬ glycol‬ 1000‬ succinate‬
(PLA-TPGS). Then, in 2013 Huang et al. 
35
 produced 
Mn3[Co(CN)6]
2
 nanocubes that can serve as MRI agents and two-
photon fluorescence (TPF). Tian et al. in 2013, reported core-shell 
Fe3O4-Cu9S8 nanoparticles for dual-modal imaging and photothermal 
therapy 
36
, useful as a probe for T2.  
Among different probes, those combining MRI and FMT imaging 
modalities have been used to evaluate morphological and functional 
changes in tumors in response to chemotherapy by monitoring tumor 
growth and protease activity
37
. Currently, nanoparticles obtained by 
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coacervation for applications in MRI as contrast medium have been 
evaluated to allow the increase of the signal encapsulating substances 
such as Gd chelates, whose free molecule is toxic into the body
30
.  
As previously reported until now most of the efforts have been 
limited to grafting contrast-enhancing agents to the surface of 
hydrophobic particles where access to water is achievable or to 
enhance the delivery by an effective encapsulation
11
. In this chapter, 
is presented a Complex Coacervation Method to produce Hybrid 
Core-Shell NanoParticles (HyCoS NPs) made of a Chitosan-core and 
a Hyaluronic Acid-shell, and to the control of their properties for 
application in the MRI and Optical Imaging Field. Indeed, HyCoS 
NPs are designed to entrap rationally a relevant clinical CA, Gd-
DTPA, enhancing its MRI performances and delivering an effective 
amount of optical tracer sufficient to achieve a high-intensity signal.  
These nanovectors are engineered to own these peculiar properties 
and, at the same time, preserve fundamental characteristic of the 
delivery (e.g. size, charge, choice of shape and materials)
10, 38
. 
Furthermore, many efforts are made to overcome the interference of 
MRI agent with the coacervation process introducing a double 
crosslinking reaction, an intrachain crosslinking (between polymer 
chains of core-shell) and an interchain one (between the polymer 
chains of the shell), able to improve the stability of the system. Then, 
using the temperature, the proposed process has been speeded up to 
reduce the reaction time and stabilize the architectures. 
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1.2 Materials 
1.2.1 NPs Production 
Chitosan (Ch) low molecular weight; Divinyl Sulfone (DVS) 118.15 
g/mol; Sodium Tripolyphosphate (TPP) 367.86 g/mol; Glacial Acetic 
Acid (CH3COOH) molecular weight 60.05; Ethanol (EtOH) 
molecular weight 46.07; Gd-DTPA molecular weight 547.57; 
Mineral Oil 0.84 g/mL at 25°C (lit.); Span80 molecular weight 
274.43; 1.005 g/mL at 20 ºC (lit.); while Hyaluronic Acid (HA) 850 
kDa parenteral grade is by Hyasis. MilliQ water is for all 
experiments. 
1.2.2 Reactants used for the functionalization of NPs  
EDC‬ (1-ethyl-3-(3-dimethylaminopropyl)‬ carbodiimide‬
hydrochloride),‬ NHS‬ (N-hydroxysuccinimide)‬ and‬ Streptavidin‬ are‬
purchased‬ by‬ Sigma-Aldrich.‬ Dyes (Cy5, Atto 633, FITC) are 
purchased by Sigma-Aldrich®. 
1.3 Method of HyCoS NPs Production 
1.3.1 Evaluation of the Phase behavior of the Ch-Acetic 
Acid-Water system 
The behavior of the Ch- CH3COOH-water system is evaluated 
experimentally starting from 1ml of water in which are added Ch and 
CH3COOH at different percentages alternatively. After each 
addition, the vial is stirred for 15 min. After the behavior of the Ch- 
CH3COOH-water system is observed, if the system resulted 
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completely solved that point was indicated on the ternary diagram 
with a green spot, alternatively with a red one. The region, in which 
the behavior of the ternary system is only partially dissolved, is 
displayed with a black line to underline the difference between the 
two different behaviors. 
1.3.2 Emulsion preparation to produce core-shell 
nanoparticles by complex coacervation 
A Complex Emulsion-Coacervation is used for the production of 
HyCoS nanostructures. 
The first step consists in the preparation of a w/o emulsion (5%/95% 
v/v) used as a template. The water phase is made of an aqueous 
solution of Ch and CH3COOH 8% v/v obtained by mixing 5 ml of 
MilliQ water at a Ch concentration ranging from 0.1% wt/v to 1% 
wt/v. Due to the hydrophobic nature of the Ch, the greater is the 
percentage of CH3COOH in the solution; the lower is the gap of 
miscibility between Ch and water. The oil phase is obtained by 
dissolving the surfactant Span80 (0.5-1% wt/v) in 45 ml of Mineral 
Oil and homogenizing for 5min at 7000rpm (by L5MA purchased by 
Silverton). The primary emulsion, obtained by mixing both phases, is 
treated for 20 minutes at 7000 rpm. Then, the solution containing 
HA, as coacervate polymer, is added dropwise and the final volume 
is homogenized at 7000 rpm for further 30 min, keeping constant the 
Temperature at 37 °C. In a different preparation, a clinical relevant 
Contrast Agents (CAs), Gd-DTPA, at a concentration of 18 mM, is 
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added to the aqueous solution containing Ch before mixing to the oil 
phase. When Gd-DTPA is added to the aqueous solution, the 
preferred volume of CH3COOH is of 10 µL to balance the acid 
nature of Gd-DTPA and to re-establish the pH conditions from 4.5 to 
5 able to favor the activation of the –COOH group. The final 
concentration of Gd-DTPA within the total emulsion is of 1.8mM. 
After the preparation of a stable primary emulsion, the coacervant 
phase, composed of 0.1% wt/v HA in a water solution of 3ml at 30% 
wt/v, is added dropwise to the w/o emulsion template and 
homogenized at 7000 rpm for 30 min. The pH and temperature are 
continuously monitored and kept at a value ranging from 4.5 – 5. 
Coacervation starts as soon as HA reaches the surface of the droplet 
template containing the chitosan solution. Two crosslinking agents 
are added to the phases, to improve the stability of the coacervate. 
The preferred formulation is the addition of TPP to the coacervant 
phase and DVS to the aqueous phase. TPP concentration ranges from 
20 – 40%wt/v increasing the pH of the coacervant phase to 10-11. 
The addition of DVS (8-24%v/v) to the aqueous phase kept the pH 
condition at the constant value of 4.5-5. DVS is always added to the 
aqueous phase to avoid an uncontrolled crosslinking reaction. The 
total formulation is stirred overnight at 300rpm at T ambient until 
coacervation completely occurs. Time of homogenization is also 
studied by stirring the w/o emulsion for 5-10-15 or 20 min at 
7000rpm while the coacervation step is performed at 30 and 60 min 
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at 7000 rpm. In different protocols, the effect of the Temperature is 
also tested and the coacervation step is maintained at high constant 
temperature for 6h to promote the evaporation of the CH3COOH or a 
controlled Temperature profile is performed from 40 to 23 °C. To 
follow the development of the chemical reaction, few microliter of 
the emulsion are collected at different time points and the formation 
of the nanoparticle is attempted by SEM. 
1.3.3 Evaluation of Encapsulation Efficiency and Loading 
Capability 
To study the Encapsulation Efficiency (EE) and the Loading 
Capability (LC) of several specific dyes, Cy5, Atto 633, FITC, are 
alternatively added to the aqueous phase at concentrations ranging 
from 0.1 to 1 mg/mL. For the determination of the EE and LC the 
protocol proposed by Ankrum et al. is followed
39
.
 
1.3.4 Bioconjugation of the HyCoS NPs 
230 µl of a solution of EDC at 70mM and 230 µl of a solution of 
NHS at 21mM are added to 500 µl of NPs to activate the carboxylic 
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groups on the external shell of HA. After 10 min of stirring, 40 µl of 
the selected dye are added. The conjugation reaction is kept under 
continuous stirring for two hours at room temperature. Purification 
protocols are performed to wash away the residual reaction 
components by dialysis or ultracentrifugation. The behavior of the 
NPs is observed in a range of pH values between 4.3 and 7. These 
pH values are chosen because: 4.3 is the inferior limit of the range in 
which the NPs result to be stable while 7 is the pH value at which in 
general are administred the injectable solutions in clinical practice. 
HCl and NaOH are added to reach the selected pH values. In 
particular, 8 µl of a solution 1M of HCl are added to 5 ml of NPs to 
reach the pH of 4. Then, the suspension is split into 10 batches of 
500 µl and kept under continuous stirring for 24h. NPs, hold at pH 4, 
are observed at different time points, 30 min, 1h, 2h, 3h, 6h, 8h, 12h, 
24h by SEM. Alternatively, NPs are treated at pH 7, by adding 10 µl 
of a NaOH solution at 1M  to 5 ml of the aqueous phase containing 
NPs at pH value of 5.5. The observation of NPs at pH 7 is done after 
30 min, 1h, 2h, 3h, 6h, 8h, 12h, 24h at SEM. The experiments are 
repeated in triplicate. 
1.3.5 Characterization of HyCoS Nanoparticles 
A Field Emission Scanning Electron Microscope (FE-SEM) by 
Zeiss, Transmission Electron Microscope (TEM) by FEI® in DRY, 
CRYO and Tomography (TOMO) modes, Confocal Microscope 
(STED Stimulated Emission Depletion) and IR spectroscopy Thermo 
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are used in order to characterize morphologically and chemically the 
system. The SEM  characterizations are made after 48 h of stirring 
withdrawing 200µl of the reaction and diluting in 50 ml of EtOH, 
after an ultracentrifugation (UC condition 15.000rpm 10min 4°C) 
and after the dialysis to control the integrity of the nanostructures. 
The SEM observations are made by collecting nanoparticles on an 
ISOPORE membrane of 100nm pore size. Nanoparticles are coated 
with 7nm Au or PtPd prior observation. The TEM analyses are 
conducted both in DRY, CRYO and Tomography (TOMO) modes. 
In the DRY mode, the samples are prepared using Formvar/Carbon 
200 mesh Cu Agar using 20µl of the suspended nanoparticles. In 
CRYO mode the samples are prepared using VITROBOT FEI 
coating Lacey Carbon film 200 mesh Cu Agar with 3µl of 
nanoparticles suspension. The conditions of VITROBOT are blotting 
time 1s, humidity upper than 70% and temperature 20°C. Confocal 
Microscopy (Stimulated Emission Depletion) STED is used to 
evaluate the fluorescence of encapsulated or conjugated NPs. The 
observed samples are prepared by drying 20µl of nanoparticles 
suspension deposited in a FluorDish. FT-IR studies are conducted to 
investigate the interaction among Ch, TPP and HA in the 
nanoparticles formation process. The IR analysis is obtained by 
measuring solid samples of raw Chitosan, HA and TPP while 150µl 
of HyCOs NPs are deposited on silicon wafers to avoid interference. 
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1.3.6 In Vitro MRI 
Analyses with Minispec 60mq BRUKER are performed to evaluate 
the‬relaxation‬times.‬300µl‬of‬nanoparticles’‬suspension‬(1mg/ml)‬or‬
Gd-DTPA solution are loaded within a glass tube. The Free 
Induction Decay sequence (FID) is used to evaluate the best value of 
the Gain to control the saturation of the signal and measure and to 
measure T2
*
 signal. In addition, the Saturation Recovery and 
Inversion Recovery sequences are used to measure T1 signal while 
the Carr-Purcell sequence (CPC) to evaluate T2. The relaxation times 
distribution is obtained by CONTIN Algorithm. The relaxation 
spectrum is normalized with respect to the CONTIN processing 
parameters. The integral of a peak corresponds therefore to the 
contribution of the species exhibiting this peculiar relaxation to the 
relaxation time spectrum
40
. Experiments are repeated at least five 
times. 
1.3.7 MRI acquisition on C57 bulb mice model 
Animal‬ studies‬ are‬ performed‬ after‬ approval‬ of‬ the‬ Institutional‬
Animal‬ and‬ Care‬ Committee‬ of‬ the‬ CEINGE,‬ Biotecnologie‬
Avanzate‬and‬the‬Italian‬Ministry‬of‬Health,‬Protocol‬n°‬49/2015-PR‬
e‬ n°‬ 50/2015-PR,‬ in‬ accordance‬ with‬ European‬ guidelines‬ of‬ the‬
2010/63/EU‬Directive‬on‬the‬protection‬of‬animals‬used‬for‬scientific‬
purposes. 
All studies are performed on SWR/J mice model under general 
anesthesia, obtained with an intraperitoneal injection of 
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tribromoethanol solution at a final concentration of 12.5 mg/ml and 
administered at a dosage of about 250 mg/kg. Once anesthetized, 
mice are prepared for venous cannulation by bathing the whole tail in 
tap water warmed at 39.0°C to obtain proper vasodilation. A lab-
made catheter, consisting of a 30 G needle mounted on a 
polyethylene tube, is delicately advanced in one of the lateral caudal 
veins, until blood could be seen in the tube. Hence, two-three drops 
of surgical glue are spilled on the needle /tail interface area and let 
dry. The tube is flushed with 20 µL of a heparinized solution and the 
tip of the tube is closed to avoid further bleeding. The mice are then 
positioned on magnetic compatible bedding within a head coil and 
the baseline acquisition is performed. Hereafter, 150 µL of the 
contrast agent solution is slowly injected, following any eventual 
reaction of the mouse or any change in the respiratory pattern. 
Acquisitions are performed every 10 minutes till one hour post 
injection, and then after three, six, eight and 24 hours. Following, the 
MRI protocol of acquisition for PET/MRI 3T Siemens reported. A 
basal MRI Acquisition has been conducted for all animals before the 
first Injection Protocol as control. T1_TSE_FS_CORE_192_1.2 
Sequence is used for each acquisition. Following the main are 
reported the mail parameters of the used sequence.  
Sequence Name: T1_TSE_FS_CORE_192_1.2 
Slices: 1.2 mm (without GAP, contiguous slice) 
Averages: 6 
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Turbo spin-echo 
Sequence duration: 10 minutes -36 seconds 
Signal to Noise Ratio: 1 
VOF: 100 x 75 
Matrix: 192 x 144 
Spatial Resolution: 0.5 x 0.5 
TR: 550 
TE: 11 
Saturation Sequence of fat (visible signal in kidneys after 3 
hours). 
 
150µl of HyCoS NPs 40µM (T1 700 ms) are injected to each subject. 
Flip Angle is kept constant because the slices are very small.  
 
After each injection, a MRI scan is performed at different time points 
to control the Gd-NPs distribution.The acquisition time is 10 
minutes. 
In the following table, the time points at which the MRI scans are 
performed after the administration of the dose are reported for each 
of the three tested subjects. 
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Subject Time Point (h) 
T1 
0:00 
0:10 
0:20 
0:30 
0:40 
0:50 
3:00 
4:00 
24:00 (1 d) 
192:00 (8d) 
T2 
0:00 
0:10 
0:20 
0:30 
0:40 
0:50 
3:00 
24:00 (1 d) 
192:00 (8d) 
T3 
0:00 
0:10 
0:20 
0:30 
0:40 
0:50 
192:00 (8d) 
Table 1: MRI acquisition at different time points: After the injection of the 
nanoparticles, Animals are scanned at different time points to follow the 
biodistribution of the complex.  
After 8h the organs of each subject (liver, Kidney, lung, spleen, 
heart, blood and brain) are collected and weighted to be analyzed by 
ICP/MS. These analyses allow to evaluate the concentration of Gd-
DTPA in each organ for each subject.  
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The DICOM files of each acquisition were stored on an external unit. 
The files were imported in dedicated software for imaging analysis 
(OsiriX
©
 Lite, Pixmeo SARL, Bernex, Switzerland). A circular 
region of interest (ROI) of about 2 mm
2
 was drawn and then saved, 
to be used in the analysis of all images. The anatomic areas studied 
were: renal cortices and medullas, the urinary bladder, the salivary 
glands. The mean intensity obtained for each organ (IO) was 
normalized to the mean muscle intensity (IM) applying the formula: 
IOnorm = IO / IM, and the result was used to calculate the percentage of 
contrast enhancement (%CE) %CE = [(Ipost – Ipre) / Ipre] * 100.  
1.4 Results  
1.4.1 Phase behavior of the Ch-CH3COOH-Water system 
Our first step is devoted to the understanding of the phase diagram of 
the ternary system Water-CH3COOH –Ch (Figure 1- 2) to improve 
the knowledge and, therefore, the stability of the aqueous phase of 
the emulsion template. The thermodynamic system is extremely 
complex and sensitive to small changes in concentration among the 
components. The low solubility of the Ch creates a gap of miscibility 
that is overcome by adding the CH3COOH dropwise. The ternary 
diagram reported in Figure 1- 1, is built analyzing the behavior of Ch 
at different concentrations of the CH3COOH solution. The red 
working points show the concentrations at which the polymer is not 
dissolved into the solution while the green working points display the 
complete dissolution of the polymer chains. The black line, which 
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draws the border of miscibility gap, shows a scratched transition area 
between the two different behaviors. For a concentration of 1% of 
Ch, the complete dissolution of Ch in 5 mL of water is reached only 
at 2µl/ml of CH3COOH. 
 
Figure 1-2: Experimental determination of the Phase Diagram of the ternary 
system Water-Acetic Acid-Chitosan. Phase diagram is obtained adding dropwise 
the acetic acid to the Chitosan and Water, allowing the complete dissolution of the 
polymer. The green spots (-●-) represent the working point showing the complete 
dissolution of the polymer.  The line drafts the miscibility gap between the two 
different behaviors.  
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1.4.2 Preparation of the Hybrid Core-Shell Nanoparticles 
(HyCoS NPs). 
Nanoparticles are produced by coacervation performed at 0,1 % wt/v 
HA, 1% wt/v Ch, 30% wt/v TPP, showing a stable behavior also in 
water. However, when Gd-DTPA is added to the aqueous phase at 
the ratio 1:1 GdCA:Ch, morphologies of the nanoparticles results 
irreversibly compromised in water (Figure 1- 3). Indeed, even if the 
coacervation is properly occurred in the presence of Gd-DTPA, as 
observed in Figure 1- 3A and 3B reporting nanoparticles in EtOH, 
the spherical shape is not preserved in water and dissolved 
completely just after few minutes. This evidence shows a strong 
interference of Gd-DTPA with the crosslinking reaction that weakens 
the effectiveness of the coacervation. To avoid the instability of the 
architectures in the presence of Gd-DTPA, we have proposed the 
introduction of a second crosslinker, DVS able to create bis-
sulfovylnil linkage between OH groups of HA
41, 42
.  
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Figure 1-3: Morphological characterization of nanoparticles by Fe-SEM: 
Coacervation performed at 0,1% wt/v HA, 1% wt/v Chitosan, 30% TPP wt/v, Gd-
DTPA:Chitosan 1:1. (A) and (B) NPs collected in EtOH while (C) NPs collected in 
water. Results clearly show that if Gd_DTPA is added to the solutions, the stability 
of the CoA NPs in water is compromised and the spherical core-shell morphologies 
are not preserved. 
 
Adding the different percentage of DVS (8%, 16%, 24% v/v), it is 
noticed that there are also some regular swelling phenomena by 
increasing the volume of DVS for NPs with and without Gd-DTPA 
(Figure 1- 4A-C). Indeed, NPs maintain their structures, avoiding the 
complete dissolving phenomena only at DVS concentration of 8%v/v 
(Figure 1- 4A). At percentage of DVS higher than 8%v/v, (Figure 1- 
4B and C) there is an increase in the size of the nanoparticles and the 
production of some irregular shapes. This effect is probably due to 
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interference between DVS and the system caused by a partial 
reaction of the crosslinker with the hydroxyl –OH groups of HA 
(Figure 1- 4B and C).  
 
Figure 1-4: Morphological characterization of nanoparticles by Fe-SEM: 
Coacervation performed at 0,1% wt/v HA, 1% wt/v Chitosan, 30% TPP wt/v, Gd-
DTPA: Chitosan 1:1. NPs collected in water obtained by using DVS at (A) 8% v/v ; (B) 
16% v/v ; (C) 24% v/v DVS collected in water. Panel reports how the stability of the c 
ore shell nanovectors is reached only for DVS at 8 % v/v. 
 
1.4.3 FT-IR analysis 
To confirm the effectiveness of the chemical reaction, an FT-IR 
analysis is performed. Indeed, the favorable pH conditions reported 
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in the literature for HA and DVS
41
 are not properly reached in our 
system, and an FT-IR study is conducted to investigate the 
interaction between the two polymers (Ch and HA) and the 
crosslinkers (TPP and DVS). In Figure 1- 5 of spectra of Ch-HA 
nanoparticles is shown. A band at 3450 cm
-1
 that can be attributed to 
–NH2 and –OH group stretching vibration in chitosan matrix is 
currently not detected in the spectra of HyCoS NPs particles
7
. The 
characteristic bands at 1658.64 cm
-1
 and 1730.92 cm
-1
 is attributed to 
C=O group stretching vibration in the HA matrix. A new sharp peak 
1641 cm
-1
 has emerged and the 1585 cm
-1
 peak of –NH2 bending 
vibration has shifted to 1582 cm
-1
. Because of –NH2 bending 
vibration shifts, the features bands at 1614 cm
-1
 and 1405 cm
-1
 have 
shifted to 1641 cm
-1
 and 1377 cm
-1
respectively. The presentation of 
P=O vibration absorption at 1269 cm
-1
 is observed, indicating the 
reaction between Ch and TPP. The peaks at 2953.42 cm
-1
, 2922.48 
cm
-1
 and 2853.39 cm
-1
 show the -CH interaction. The characteristic 
peaks for DVS show absorptions at 1119.76 cm
-1
 (S=O symmetric 
stretching vibrations) and 720.99 cm
-1
 (S−C‬stretching‬vibrations). 
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Figure 1-5: Linkage among the reactive groups analyzed by FT-IR. 
 
The DVS has an effect on the –OH groups of the HA chains and the 
favorable condition for this pH reaction is between 10 and 12. 
Furthermore, the linking between the aminic groups of Ch and the 
phosphoric groups of TPP and the –COOH groups of HA is not well 
promoted due to the strongly acid conditions of the chitosan-water 
phase. The acid state of the Ch phase is essential not only for the 
complete dissolution of the Ch in the CH3COOH solution but also 
for the behavior of the Ch chains. In fact, at strongly acid condition, 
even if more groups are activated, they are set in a shape not 
favorable to the interaction with the TPP. On the contrary, at weak 
acid conditions, even if there are less free amine groups, they are set 
in a more favorable shape that allows them to interact with TPP 
through the 𝑃3𝑂10
5−. To improve the stability of the polymeric NPs 
59 
 
different percentage of the two crosslinkers are tested. As previously 
shown 10%, 20% and 30% wt/v are tested for TPP while 8%, 16%, 
24% v/v are tested for DVS. The results show not only a different 
stability of NPs in water but also a variation in their size. Increasing 
the TPP volume from 10% wt/v to 30% wt/v, the stability of the NPs 
is improved, and, at the same time, the size of the NPs decreases. 
The effect obtained in the case of DVS is completely different. In 
fact, an increasing of DVS percentage results in both an increasing of 
the size and the development of irregular shapes. It highlights the 
difficult of DVS to spread through the emulsion in the presence of a 
high concentrated oil phase. DVS concentration of 8%v/v and TPP 
concentration of 30%wt/v produce the stabilization of HyCoS NPs 
with a size in a range from 50nm to 200nm preserving also the 
coacervation process. It is important to note that the percentage of 
TPP is also increased from 20% to 30% wt/v in the HA phase (pH 
10-11) to reach the final pH of the reaction (pH 5). In these 
conditions, the final values of pH is about 5, making stronger the 
linker between the two polymers. For the final reaction at pH value 
lower than 5, the crosslinking reaction of TPP between Ch and HA is 
not completed because the –COOH groups of HA are not fully 
activated while at pH higher than 5, available amine groups of Ch to 
the reaction are reduced. 
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1.4.4 Effect of the Temperature on the coacervation step 
Furthermore, to minimize the time of the coacervation step, different 
gradients of temperature are tested (Figure 1- 6). The intent is to 
promote both the evaporation of the CH3COOH and the chemical 
reaction of inter and intra chains. Several isothermal profiles are 
studied but the formation of nanoparticles is only observed at 35 °C, 
confirming that the coacervation step properly occurs even if the 
morphologies are not stable in water, probably due to an 
uncompleted chemical reaction among the compounds. Later, 
starting with the isothermal observations, we have studied the 
combination of an isothermal profile with a cooling step. In this 
experiment, the demixing is visible after 5,5 h of isothermic step at 
35 °C followed by a ramp at 8°C/h from 35°C to 23°C, spending 
about 1.5 h to reach the final stable morphologies. It is important to 
note that, after the isothermal step, when the demixing visibly 
occurs, the cooling of the emulsion should be suddenly performed to 
avoid aggregation phenomena among the nanovectors.  
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Figure 1-6: Profile of Demixing Reaction. In the graph are shown the profiles of 
demixing of the coacervation at different gradients of temperature. Temperature 
enables a reduction of the process time from 24h to 6.5-7 h. Best results are 
obtained performing an Isothermal at 35 °C for 5.5h and a ramp from 35°C to 23°C 
for 1.5h. In details, after the isothermal step, the reaction of coacervation occurs, 
and a demixing of the prepared solution is observed. After the demixing phase, a 
variation of the temperature should be suddenly performed to avoid aggregation 
phenomena and the destruction of the nanovectors. Indeed, as soon as the 
demixing phase occurs, the produced nanoparticles are unstable and a further 
support of temperature needed to increase the stability of the system. 
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Indeed, an additional cooling step is needed to increase the stability 
of the system. A reduction of the demixing time involves a 
decreasing in the evaporation time of the CH3COOH, a faster 
coacervation reaction and an acceleration of the DVS reaction with 
the –OH groups on the polymer chain of HA. The use of temperature 
allows a reduction of the duration of time of coacervation from 24h 
to 6,5-7 h and it also allows a comparison in terms of swelling 
behavior with HyCoS NPs obtained at constant room Temperature, 
as reported in the next paragraphs. Images reported in Figure 1- 5 
show nanoparticles obtained at the different demixing profile of the 
reaction at different temperatures. NPs obtained performing an 
Isothermal at 35 °C for 5.5h show the best stability and a defined 
core-shell morphology (Figure 1- 7 -●-). In Figure 1- 7E, a 
morphological characterization of core-shell nanoparticles obtained 
by TEM is shown. In details, several nanoparticles of 70 nm 
produced by our standard coacervation are reported while, in Figure 
1- 7F, an enlargement is displayed highlighting the perfect core -
shell architecture.  
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Figure 1-7: SEM images of nanoparticles produced by different calorimetric profile 
(A-D): A (●)- NPs obtained performing an Isothermal at 35 °C for 5.5h; B (□)- Result 
obtained performing an Isothermal at 40 °C. No demixing is observed; C (Х)- Result 
obtained performing an Isothermal at 28 °C until demixing (after 17h).D (▲)-Result 
obtained performing an Isothermal at 23 °C until demixing (after 20h).  After that 
the demixing occurs, a ramp to 23°C for 1.5h is performed to complete the 
separation and to stabilize the morphologies. Morphological characterization of 
nanoparticles by TEM (E-F): Core-shell Gd-DTPA-NPs obtained without the use of 
the temperature profile collected in water. (E) NPs obtained at 0,1% wt/v HA, 1% 
wt/v Chitosan, 30% TPP wt/v, Gd-DTPA: Chitosan 1:1 and 8% v/v DVS and (F) 
Magnification of the previous image. 
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1.4.5 pH-responsive behavior 
Preliminary results on HyCoS NPs reports a peculiar yet interesting 
pH-sensitive behavior of the nanovectors. In details, for HyCoS NPs 
produced at room Temperature, at pH 4, they maintain their stability 
until the first hour, but after this time they dissolve completely. On 
the contrary, at pH 7 they preserve their stability at every different 
time (30 min, 1h, 2h, 3h, 6h, 8h, 12h, 24h). Nanoparticles obtained 
by using the cooling step do not seem to be pHsensitive and remain 
stable at any pH condition until 24 hr. Further details are reported in 
Figure 1- 8, showing images of the different behavior of the NPs by 
changing the pH conditions. 
 
Figure 1-8:pH-Responsive NPs:The behavior of the obtained NPs are tested at pH 4 
and 7 at different time points: NPs maintained at pH 4 after 30 min (A); NPs 
maintained at pH 4 after 1h (B); NPs maintained at pH 7 after 30 min (C); NPs 
maintained at pH 7 after 24h (D).  
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This characteristic pH triggering could provide significant advances 
in the use of the vector for the treatment of tumor pathologies. In 
fact, the tumor environment, besides to being devoid of oxygen, is 
also characterized by an acid pH by an impaired operation of the 
lymphatic system to drainage of fluids that instead tend to 
accumulate inside the interstitial space
38, 43-45
. First, the use of 
macromolecules and, later, nanocarriers is exploited to study the 
potential acidity of the tumor microenvironment to release any drugs 
encapsulated in the carriers directly in the tumor area to have a 
diffusion of the active agents within the tumor matrix and, therefore, 
performed a better diagnosis or therapy. 
1.4.6 In vitro MRI 
As already reported in the Materials and Method Section, ICP-MS is 
used to assess the concentration for Gd-DTPA loading within the 
HyCoS NPs. This data are also useful to evaluate the relaxometric 
properties of the nanovectors. Results clearly demonstrate that a 
relaxation rate T1 of 1720 ms is achieved with 20 µM of Gd-loaded 
HyCoS while 100 µM of Gd-DTPA solution is required to reach 
similar T1 (1724 ms) (Figure 1- 9). This effect of enhanced relaxivity 
potentially allows the administration of a reduced dosage of contrast 
medium keeping the same T1 signal intensity. This peculiar behavior 
is probably ascribable to the combination between the hydrophobic 
nature of the Ch and the hydrophilic character of the HA tuning the 
water exchange with the coordination sites of the metal r. Intensity 
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on the ordinate axis is not reported because it represents a qualitative 
value related to the detector of the instrument and it is not considered 
in the MRI evaluation  
 
Figure 1-9: In vitro MR:. Relaxation rate distributions of Gd-DTPA in solution at (-
▼-)10µM; 60 µM (- -), 100 µM (-▲-); and HyCoS NPs loaded with Gd-DTPA at (-
■-)The results show an enhancement in r1 of 6 times compared to the free Gd-DTPA. 
T1. 
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1.4.7 Optical Imaging and bioconjugation 
In Figure 1- 10, results related to the optical imaging of the 
nanoparticles observed under STED are reported. The first image 
(Figure 1- 10A) shows nanoparticles obtained by coacervation 
performed at 0,1% wt/v HA, 1% wt/v Ch, 30% TPP wt/v, Gd-DTPA: 
Ch 1:1, 8% v/v DVS. Cy5 ranging from 0.1 to 1 mg/mL (633 nm) 
are encapsulated into the NPs while, in Figure 1- 10B and C, the NPs 
are conjugated with FITC (488 nm). In (Figure 1- 10D), an intensity 
profile of the conjugated NPs of Figure 1- 10C is reported. Figure 1- 
10B and C reports the fluorescence due to the conjugation of the dye 
exclusively on the shell, highlighting the non-fluorescent core not 
involved in the reaction. We have also proved that nanoparticles are 
highly stable even after the reaction protocols and that are capable of 
preserving their cargo of Gd-DTPA as so their enhanced 
relaxometric properties. This is an important goal considering the 
relevance to candidate our product for the in vivo Integrated 
Multimodal Imaging. 
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Figure 1-10: Optical Imaging of the nanoparticles observed under fluorescent 
microscope (Stimulated Emission Depletion STED): NPs obtained at 0,1% wt/v HA, 
1% wt/v Chitosan, 30% TPP wt/v, Gd-DTPA: Chitosan 1:1, 8% v/v DVS and Gd-DTPA: 
(A) Gd-DTPA and 100µl of Cy5 1mg/ml (633 nm) are encapsulated into the NPs;(B) 
The obtained nanoparticles are conjugated with FITC (488nm). The image shows the 
difference between the core and the shell structure;(C) Magnification of the image 
reported in figure (B); (D) intensity profile of fluorescent Nanoparticle in (B) 
calculated by the Region of Interest method (ROI).  
1.4.8 In vitro cytotoxicity 
Typically, structural alterations of NPs in aqueous solutions, in cell-
culture medium, might also affect and change the final results of the 
in vitro toxicological studies. Therefore, Cytotoxicity tests are 
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essential to preliminary asses the biocompatibility of the HyCoS 
NPs. Nasti et al.
46
 suggest the cytotoxicity of the chitosan/TPP 
nanoparticle to be mostly dependent on their internalisation, which 
on its turn seems to be scarcely dependent on size and clearly 
dominated by surface composition/charge: indeed it is well known 
that positively charged nanoparticles are more quickly internalised 
than negatively charged ones and the HA-coating markedly reduces 
the nanoparticle toxicity. Results of chemical characterization studies 
show that the amount of covalently incorporated DVS into the 
structure of HA is largely controlled by the crosslinker concentration, 
thereby determining the mechanical stability and resistance against 
enzymatic degradation. Lai demonstrates good cytocompatibility of 
HA sheets treated with concentrations of DVS ranging from 0 to 50 
mM.
47, 48 44 . 
For this study the toxicity of HyCoS NPs is tested using 
an WST-1 assay, which is based on the conversion of water-soluble 
tetrazolium salt (yellowish in color) to water insoluble formazan 
(purple color) by living cells. The WST assays have appeared to be 
advantageous over MTT because of its solubility in tissue culture 
medium and storage condition. 
Scalar concentrations of HyCoS NPs are tested in a range between 
200 ng/mL and 100 µg/mL. It is evidenced that the NPs showed no 
detectable cytotoxicity in vitro (Figure 1- 11). 
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Figure 1-11: In vitro cytotoxicity: A549 cell viability expressed as a percentage of 
the value obtained with a concentration of hyaluronic nanoparticles in a range 
between 10 µg/mL and 100 µg/mL for three different time intervals. The error bars 
represent the standard deviations calculated from three independent experiments. 
 
1.5 In vivo MRI analysis 
Analysis is conducted on a PET/MRI 3 Tesla scanner to evaluate the 
% contrast enhancement (CE) of the images for a scanner used in a 
clinical practice. Two samples are studied: HyCoS NPs (Figure 1-12) 
and Gd-DTPA (Figure 1- 13). 
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In details, a multivariate analysis of variance for repeated measures 
(RM-MANOVA) is used to study the selected parameters of the 
treatment group with Gd-DTPA loaded HyCoS NPs and Gd-DTPA. 
No significant effect of the treatment group could be detected for 
renal medulla (0.96) and salivary glands (P=0.65) (Figure 1- 12). The 
urine %CE results significantly affected by the interaction of time 
over group (P=0.0008), with the HyCoS NPs having the highest 
%CE than Gd-DTPA treated mice (Figure 1- 13).  
A significant difference between groups was detected for the renal 
cortex (P=0.03) and a significant effect of the interaction of time 
over the group (P=0.0007) is recorded, as well, with HyCoS NPs 
showing a higher and increasing %CE from 10 minutes to 1 hour 
(Figure 1- 12).  
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Figure 1-12: Dynamic MRI study: coronal view of a mouse treated with HyCoS NPs. 
The slices selected include the kidneys (upper row) and the urinary bladder (lower 
row). Baseline acquisition (A, E) is followed by intravenous injection of the HyCoS 
NPs suspension, and the mice are scanned at 30 minutes (B, F), one hour (C, G) and 
3 hours (D, H) post injection. The same window level (WL=320) and window width 
(WW=610) are used in all images. 
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Figure 1-13: Dynamic MRI study: Coronal view of a mouse treated with Gd-DTPA. 
The slices selected include the kidneys (upper row) and the urinary bladder (lower 
row). Baseline acquisition (A, E) is followed by intravenous injection of the Gd-DTPA 
solution, and the mice are scanned at 30 minutes (B, F), one hour (C, G) and 3 hours 
(D, H) post injection. The same window level (WL=320) and window width 
(WW=610) are used in all images. 
No accumulation of Gd-DTPA is shown from ICP-MS analysis 
following repeated administrations of HyCoS NPs (see Appendix par 
5.2).  
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1.6 Discussion  
The described process has led to the generation of NPs with a 
Chitosan core and an outer shell of HA. The innovations of process 
consist of a double crosslinking, by TPP and DVS, which allows 
controlling the stability and the degradation behavior of the two 
chosen polymers, and a heating/cooling step of the reaction to speed 
up the coacervation process and control the swelling behavior. TPP 
is considered as a small ion with a triple negative charge which is 
dissolved into the HA phase, able to link the hydrophobic core of Ch 
to the hydrophilic shell of HA. On the HA side, –OH(HA) and -
COOH-(HA) can coexist in the tripolyphosphate solution at all pH 
values promoting the interchains reaction between the two polymers. 
Indeed, when the solution containing the HA and the TPP reaches the 
surface of the droplet template containing Ch and DVS, a 
coacervation layer has firstly formed on the surface of the Ch 
droplets, and anions and –COOH- (HA) reacts with caution. 
Simultaneously, the –OH groups of HA are linked by DVS, 
stabilizing the shell. (Figure 1- 14A) while TPP partially diffuses 
inside the template through the coacervation layer reaching the core 
and creating hydrogen bonding, linking the Ch core to the layer of 
the HA firmly (Figure 1- 14B). However, because HA has a 
molecular weight larger than the Ch, and Ch is a hydrophobic 
polymer, both HA and TPP cannot deeply penetrate the core, 
probably reaching only the surface of the Ch template. The above-
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reported steps are here described for the first time and represent a 
significant advance in the understanding of the control of the 
interference due to the presence of Gd-DTPA in the crosslinking 
reaction and the coacervation process. A unique aspect of this system 
also lies in the double crosslinking promoting both an intrachain link 
among HA polymer chains and interchain links among Ch and HA 
able to control the loading of Gd-DTPA and its relaxometric 
properties. Furthermore, the TPP is added in HA coacervate phase 
while in literature is typically added to the chitosan phase. In details, 
phosphoric groups of TPP interact with the amine groups of Ch and 
with –COOH and –OH groups of HA, while sulfuric groups of DVS 
links –OH groups of HA. The reverse use of the two crosslinkers is 
fundamental to avoid the linkage between the chains of HA before 
the coacervation reaction occurs.  In fact, the DVS is not able to 
interact with the Chitosan chains while TPP can link HA chains only 
partially 
46
. The pH of the single polymeric solutions is deeply 
studied to control perfectly the reverse use of crosslinkers, t. Indeed, 
the pH of the Ch and HA phase are controlled to allow the activity of 
the crosslinkers only during the coacervation process and not during 
the preparation of the polymer solutions. The thermodynamics of the 
coacervation process can be explained in 3 steps by a ternary phase 
diagram at a specific heating/cooling step (Figure 1- 14C). First, 
referring to (Figure 1- 14C-I) after the preparation of the primary 
emulsion, the complete dissolution of the Ch in water is reached 
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through the utilization of the CH3COOH. The working point is 
located outside of the miscibility gap that exists between water and 
Ch. In the second step (Figure 1- 14C-II), the Coacervation phase is 
added to the primary emulsion, promoting the dilution of the water 
phase: in this condition, the concentration of the CH3COOH solution 
decreases below the saturation limit. At the same time, keeping 
constant the Temperature, CH3COOH continues evaporating, 
inducing a further shifting of the working point in the miscibility 
gap, leading to the coacervation of HA on the chitosan template. In 
the last phase (Figure 1- 14C-III), a controlled cooling step is 
performed to increase the miscibility gap able to promote a faster 
supersaturation‬and‬the‬stability‬of‬the‬nanoparticle’s‬architecture.  
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Figure 1-14: Description of Double Crosslinking Reaction: A) On the left the ionic 
interaction between TPP and Chitosan is described; later a crosslinking between 
Chitosan and HA is created through the TPP, on the right, in the last step the 
crosslinking between HA and DVS is obtained. B) Diffusion and formation of double-
crosslinked core-shell. Schematical representation of the crosslinking at the 
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interface between the core and shell structure. C) A schematical explanation of the 
process by the phase diagram change: I- After the preparation of the primary 
emulsion, disperse phase contains a homogeneous solution. Therefore, the working 
point represented in the phase diagram is located in the region of complete 
miscibility between water and Chitosan (brown area).  
II- Solution containing the coacervate is added to the primary emulsion, promoting 
the dilution of the disperse phase, promoting the supersaturation of the solute in 
the disperse phase and inducing the precipitation of the chitosan. At the same time 
keeping constant the temperature, Acetic acid continues to evaporate causing the 
further shifting of the working point into the miscibility gap. This last step will 
complete the formation of the chitosan template and the HA coacervation; 
III- In the last phase,  a controlled cooling step is performed to increase the 
miscibility gap able to promote a  faster supersaturation and to enhance the 
stability of the nanoparticle’s architecture. 
 
The obtained HyCoS NPs result stable and retain their cargo even 
after the conjugation of fluorescent molecules, making them 
particularly suitable for multimodal imaging applications. Indeed, the 
process conditions allow the formation of the core-shell structure 
while the entrapment of Gd-DTPA is reached through the 
crosslinking reactions. The proposed approach describes the 
successful conditions to obtain the production of HyCoS 
Nanoparticles with improved MRI properties. This effect can be 
explained according to the Solomon Bloemberg model
49
. Indeed, in 
this theory, the metal complex can be schemed as having separate 
coordination spheres, the Inner Sphere (IS) and the Outer Sphere 
(OS) both described by the characteristic correlation times, such as 
the residence time of the coordinated water molecule‬(τM),‬which‬in‬
turn determines the rate of the coordinated water molecule 
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exchanging‬with‬ the‬ bulk,‬ and‬ the‬ rotational‬ correlation‬ time‬ (τR),‬
which is how quickly the contrast agent is tumbling in solution and 
the‬translational‬diffusional‬time‬(τD), which represent the diffusion 
of water molecules in the bulk near to the Gd complex
49, 50
. Because 
of these findings, we can assert that the improved MRI performances 
result from the double crosslinking able to control the entrapments of 
the Gd-DTPA at the Chitosan–HA interface and, therefore, to tune its 
physical characteristic parameters responsible for the relaxometric 
properties. The presented approach leverages the use of the 
coacervation kinetic and the crosslinking reaction, promoting the 
diffusion and exchange of the components at the interface HA-Ch 
and leading to a peculiar environment able to boost the relaxometric 
properties. The absence of these specific conditions will result in the 
absence of the MRI signal or even of the improved performances due 
to the hydrophobic nature of the Chitosan that would not allow the 
water exchange with the metal chelate limiting its relaxivity.  
1.7 Conclusions 
For diagnostic techniques, in particular MRI, the optimization of the 
size of particles obtained by complex coacervation is limited for the 
complexity of obtaining stable nanostructures in combination with a 
Gd-based contrast agents. 
We obtained core-shell polymer NPs, which can be encapsulated 
with both Gd-DTPA and a Dye for Dual Imaging applications 
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through a complex coacervation that exploits an innovative double 
crosslinking to improve the stability of the nanostructure overcoming 
the interference of the coacervation process with the Gd-DTPA. 
Furthermore, the adjustment of the process parameters, the 
coacervation and chemical reaction kinetic promotes the 
interpolation of the hydrophobic core with the hydrophilic shell, 
controlling the water exchange and, consequently, the relaxation rate 
T1, enhancing the MRI signal at reduced concentration compared to 
the relevant clinical CAs.  
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CHAPTER 2 
2 Functionalized HyCoS NPs for in vivo optical 
imaging applications: the case study of a B-
cell lymphoma.  
 
 
Figure 2-1: Graphical representation: Multimodal designed nanovector for MRI and 
optical imaging applications. 
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2.1 Introduction  
Tumors‬are‬abnormal‬clusters‬of‬cells‬formed‬by‬alteration‬of‬genes‬
which‬induce‬a‬single‬cell‬to‬proliferate,‬giving‬rise‬to‬a‬large‬number‬
of‬ elements,‬ all‬ equal‬ to‬ the‬ cell‬ that‬ has‬ undergone‬ the‬ "tumor‬
transformation".‬ Due‬ to‬ this‬ transformation,‬ the‬ cells‬ and‬ their‬
progeny‬ are‬ more‬ or‬ less‬ completely‬ released‬ from‬ the‬ normal‬
mechanisms‬of‬control‬of‬the‬body1.‬Cancer‬is‬due‬to‬many‬different‬
causes‬with‬ include‬environmental‬ influences,‬ageing,‬ life‬style‬and‬
predisposition‬and‬in‬an‬attempt‬to‬predict‬the‬cynical‬behavior‬of‬a‬
tumor‬ and‬ to‬ establish‬ useful‬ criteria‬ to‬ treatment,‬ tumors'‬
classification‬ is‬ based‬ on‬ the‬ degree‬ of‬ cytologic‬ and‬ histologic‬
differentiation,‬clinical‬stage‬or‬protocols‬that‬describe‬the‬extent‬of‬
the‬tumors’‬diffusion2.‬Tumors‬of‬low‬degree‬are‬well‬differentiated,‬
while‬ those‬ of‬ high‬ degree‬ tend‬ to‬ be‬ anaplastic.‬ The‬ degree‬ of‬
cytologic‬ and‬ histologic‬ differentiation,‬ which‬ are‬ necessarily‬
subjective‬ and‬ at‬ best‬ semi-quantitative,‬ based‬ on‬ the‬ degree‬ of‬
anaplasia‬ and‬ the‬ number‬ of‬ proliferating‬ cells. The‬ presence‬ of‬
different‬features‬as‬shape‬or‬regularity‬of‬cells‬identifies‬a‬tumor‬as‬
well‬differentiated‬or‬ the‬opposite,‬ the‬cells‬of‬poorly‬differentiated‬
tumors‬ show‬ a‬ very‬ low‬ similarity‬ with‬ their‬ normal‬ counterpart.‬
Rapid‬or‬abnormal‬growth‬ is‬made‬evident‬by‬ the‬high‬numbers‬of‬
mitoses,‬ atypical‬ mitoses,‬ nuclear‬ pleomorphism‬ and‬ giant‬ cell‬
tumor.‬ Most‬ of‬ the‬ schemes‬ classify‬ tumors‬ in‬ 3‬ or‬ 4‬ degrees‬ of‬
malignancy‬growing.‬The‬general‬correlation‬between‬the‬cytological‬
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degree‬and‬the‬biological‬behavior‬of‬a‬tumor‬is‬not‬immutable.‬The‬
choice‬ of‬ a‬ surgical‬ conduct‬ or‬ selection‬ of‬ treatment‬ modality‬ is‬
influenced‬more‬by‬the‬stage‬of‬a‬tumor‬than‬by‬its‬grade‬cytology.‬
The‬criteria‬generally‬used‬to‬classify‬a‬tumor‬include‬the‬size‬of‬the‬
tumor,‬ the‬extent‬of‬ local‬growth,‬ if‬ it‬ contains‬all‬ internal‬body‬or‬
even‬ out‬ of‬ it,‬ the‬ presence‬ of‬ lymph‬ node‬ metastases‬ and‬ the‬
presence‬of‬distant‬metastases.‬These‬ criteria‬have‬ been‬codified‬ in‬
the‬ international‬ system‬ of‬ TNM‬ staging‬ of‬ tumors,‬ where‬ T‬
indicates‬ the‬ size‬ of‬ the‬ primary‬ tumor,‬ N‬ indicates‬ metastasis‬ to‬
regional‬ lymph‬nodes‬ and‬ the‬ presence‬ and‬M‬extension‬ of‬ distant‬
metastases. 
The tumor cells essentially behave in two ways, giving rise said 
benign tumors and other malignant said and liquid
a
 and solid
b
 tumor
3
. 
Differently from malignant tumors, benign tumors are composed of 
mature or nearly mature cells, which possess the features normally 
present in the cell type belonging to the first transformed cell. 
Furthermore, benign tumors appear to be localized, having reached a 
                                                          
a
 Leukemias ("liquid cancers" or "blood cancers") are cancers of the bone 
marrow (the site of blood cell production). The disease is often associated 
with the overproduction of immature white blood cells. These immature 
white blood cells do not perform as well as they should, therefore the 
patient is often prone to infection. Leukemia also affects red blood cells 
and can cause poor blood clotting and fatigue due to anemia.  
b
 An abnormal mass of tissue that usually does not contain cysts or liquid 
areas. Solid tumors may be benign (not cancer), or malignant (cancer). 
Examples of solid tumors are sarcomas, carcinomas, and lymphomas. 
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certain size, they cease to grow, and from that time remain stationary 
or in some cases smaller. Differently malignant tumors generally 
derived from immature cells, the tissues that hold in reserve to 
replace wounds or lost items for injuries or diseases. In normal 
conditions, these immature cells before multiplying and completing 
their maturation, acquire organelles and properties, which allow them 
to the effective performance of the duties for which they are 
programmed. When neoplastic transformation affects immature 
daughter cells sometimes progressing towards a certain degree of 
maturity, are still immature at times, to the point that you do not 
always understand what type of cell they belong. In each case, the 
elements that have undergone the transformation tumor multiply with 
great rapidity without limits, and are completely subtracted in each 
adjustment. The tumor may expand as much as its mass or crevice 
available; creeps offshoots that fit into nearby organs deforming the 
structure and impair its function. In relation to the ways of 
propagation easier, metastases are found mainly in lymph nodes 
district but are also frequent distant metastases, which are derived 
from cells transported by the blood stream
4
. The malignant tissues 
are made up of cells in continuous and unlimited proliferation, 
survival and expansion which has only one limit: the contribution of 
nutrition. The presence of tumor cells in the connective adjacent 
tissue induces the formation of a structure of support in the context 
of which develops of newly formed blood vessels
5
. All these 
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characteristics aim to generate a specific representative 
microenvironment. The tumor microenvironment is completely 
different from that of healthy tissue starting from the blood vessels. 
Blood vessels deliver oxygen and nutrients to every part of the body, 
but also nourish diseases such as cancer
5
. The tumor vasculature is 
highly heterogeneous and does not conform to the standards of 
normal blood vessels
6
. Macroscopically it is possible to define two 
categories of tumor blood vessels: a peripheral one and a central 
one
5
. Microscopically the tumor vessels can be classified into nine 
categories: arteries and arterioles; non-fenestrated, fenestrated, and 
discontinuous capillaries; blood channels; capillary sprouts; 
postcapillary venules; venules and veins; and arteriovenous 
anastomoses
7
. The large and small arteries and arterioles are invested 
from smooth muscle cells and are capable of vasomotor adjustments. 
The terminal arterioles, the next branching order of arterial vessels, 
are invested proximally in vascular smooth muscle that gradually 
decreases until a single smooth muscle cell, spirally wrapped, marks 
the end of the muscular investment
6
. This final smooth muscle cell is 
referred to as the precapillary sphincter and serves as the final 
control site for blood flow into the capillary bed. Capillaries are 
vessels made of endothelial cells surrounded by a basement 
membrane. These vessels are devoid of smooth muscle cells and 
hence are incapable of active vasoconstriction/vasodilation
6
. They 
are ideal for the exchange of material between the blood and tissues. 
92 
 
Capillaries can be divided into three categories based on their wall 
structure: non-fenestrated (continuous); fenestrated; discontinuous
7
. 
Non-fenestrated capillaries are the most common type and are 
located in the skin, connective tissue, skeletal and cardiac muscle, 
alveolar capillaries of the lung, and the brain. In fenestrated 
capillaries, there are fenestrae or transendothelial circular openings 
of about 400-800 Å between the lumen and interstitium across the 
endothelial cells. These fenestrae may be open or covered by a thin 
60-80 Å layered diaphragm similar to the diaphragm of vesicles. 
Discontinuous capillaries have large diameters and wide opening 
between endothelial cells
7
. The production process of these blood 
vessels following the creation of the tumor mass is called 
angiogenesis
8
. The angiogenesis process is a complex process of 
combination between factors which promote the formation of new 
blood vessels and those that inhibit this process. The loss of a correct 
balance between these elements causes the increasing of the blood 
vessel formation to the development of tumor diseases
6
. Between the 
different factors which are involved in the angiogenesis process there 
is the vascular endothelial growth factor (VEGF)
c
 which can induce 
the division of cultured endothelial cells thus indicating a direct 
                                                          
c
 Vascular endothelial growth factor (VEGF) is a chemical signal produced 
by cells that stimulates the growth of new blood vessels. It is part of the 
system that restores the oxygen supply to tissues when blood circulation is 
inadequate. VEGF's normal function is to create new blood vessels during 
embryonic development, new blood vessels after injury, and new vessels 
(collateral circulation) to bypass blocked vessels.  
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action on these cells
9
. These new formed vessels supply the tumor of 
blood, in practice, oxygen and nutrients
10
. Very often, however, and 
especially in more aggressive tumors, in rapid growth, supplies are 
insufficient; it is not uncommon that large portions of the tumor 
remain suddenly without nutrient intakes and should be met 
necrosis
11
. This explains why the expansion of tumors is often 
irregular and subject to unpredictable regressions
12
. What it is going 
to determine is an environment made up of blood vessels resulting in 
conditions of oxygen deficiency, hypoxia, and high acidity
13,14
. The 
hypoxia causes changes in genetic activity that promotes the 
migration of endothelial cells through healthy tissue. Radiation and 
chemotherapy treatments used in the treatment that requires oxygen 
to kill tumor cells fail to do their job, immune cells that should attack 
the cancer cells cannot perform their function because of the acidity 
of the environment and the lack of oxygen
6
. With the passage of time 
the necrotic part developing in the center of the tumor increases in 
size due to the increasing difficulty on the part of the blood vessels to 
provide the necessary nutrients and oxygen, while the outlying areas 
increase thanks to the acquisition of the same from the outside
13
. So, 
the vascular-extravascular exchange is a key element in the study of 
tumors
15
. In normal tissues, substances that cross the blood vessels 
do not accumulate in the interstitial tissues but they are drained by 
the lymphatic system differently from what happens in the tumor 
tissues
16
. The tumor microenvironment 
17
 is characterized by the 
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presence of different kinds of cell, including endothelial cells, 
pericytes, smooth muscle cells, fibroblast, carcinoma-associated 
fibroblasts, myofibroblasts, neutrophils, carcinoma associated-
fibroblasts, eosinophils, basophils, mast cells, T and B lymphocytes, 
natural killer cells and antigen presenting cells APC, such as 
macrophages and antigen presenting cells
4
. Because of poor and 
abnormal vascular development, the majority of solid tumors 
presents median O2 levels lower than those of the tissue of origin
4
. In 
addition, the hypoxic areas are characterized by low levels of 
glucose, acid pH and cause an increase in the expression of proteins 
related to angiogenesis
14
. The hypoxic microenvironment present in 
solid tumors influences not only cancer cells, but also non-neoplastic 
stromal cells, such as macrophages and fibroblasts and gives the 
tumor a greater aggressiveness and an increased metastatic 
potential
13
. This effect seems to be due to overexpression in a 
hypoxic environment, gene products that can promote tumor 
progression allowing the cells to adapt to the deprivation of food and 
to escape from a hostile environment. Furthermore, the hypoxic 
tumor cells provide a microenvironment that facilitates the radio - 
and chemo – resistance, in fact, the hypoxic tumor cells are 
significantly more resistant than normal oxygenated cells to ionizing 
radiation
18
. It is due because, while in normoxic conditions the 
oxygen reacts with the radicals produced in the DNA damaged from 
ionizing radiation staring permanently, in the absence of oxygen 
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most of these radicals is converted into a form not damaged, 
following the donation of hydrogen by non-protein sulfhydryl groups 
present in the cell. The lack of oxygen also significantly affects the 
response of tumor cells to hyperthermia. Based on the results of 
experiments in preclinical models have proposed a classification of 
anticancer drugs into different groups, depending on their 
susceptibility to O2 
4
. There is plenty of research showing the link 
between acidic pH and cancer. Cancer thrives in an acidic 
environment and does not survive in a normal, more alkaline 
environment. Cancer cells make body even more acidic as they 
produce lactic acid. , in fact acidic water holds very little oxygen, so 
the more acidic your cells are, the less oxygenated they will be. 
Diffusing into the normal tissue, the acid causes normal cell death 
which in turn allows the tumor to expand
14
. The possibility to have 
an early and effective diagnosis of a tumor disease can increase even 
chances of survival that ensuring patients receive the most 
appropriate treatments
19
. As‬it‬ is‬known,‬ the‬treatment‬of‬cancer,‬ in‬
general,‬more‬likely‬to‬succeed‬in‬the‬early‬stages.‬ 
Contrast‬media‬ play‬ an‬ important‬ role‬ in‬ allowing‬ the‬ display‬ of‬ a‬
target‬ with‬ most‬ conventional‬ techniques‬ (magnetic‬ resonance‬
imaging‬(MRI),‬computed‬tomography,‬optical‬and‬x-ray‬imaging‬(x-
ray‬ CT)20.‬ However,‬ most‬ of‬ the‬ current‬ contrast‬ agents‬ show‬
instability‬ in‬ vivo,‬ poor‬ targeting,‬ and‬ an‬ uncontrolled‬ release.‬ In‬
addition,‬current‬in‬vivo‬imaging‬techniques‬are‬not‬always‬capable‬
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of‬detecting‬tumors‬in‬the‬early‬stages‬because‬of‬their‬limited‬size.‬
Molecular‬ Imaging‬ (MI)‬ is‬ a‬ technique‬ that‬controls‬ the‬changes‬ in‬
vivo‬ at‬ the‬ molecular‬ level‬ in‬ order‬ to‬ detect‬ diseases‬ at‬ an‬ early‬
stage.‬ In‬ this‬way,‬doctors‬are‬able‬ to‬come‬up‬with‬a‬personalized‬
therapy‬for‬the‬patient‬by‬examining‬closely‬the‬region‬of‬the‬body.‬
For‬ this‬ purpose,‬ vectors‬ are‬ used‬ for‬ the‬ transport‬ of‬ polymer‬
fluorescent‬ agents‬ because‬ their‬ physical-chemical‬ properties‬ offer‬
several‬ advantages‬ including‬ facilitation‬ of‬ the‬process‬ endocytosis‬
and‬cellular‬interaction;‬passing‬large‬amounts‬of‬the‬drug;‬ability‬of‬
functionalization‬of‬surfaces‬with‬a‬variety‬of‬molecular‬signals‬and‬
receptors‬for‬targeting,‬and‬theranostics‬capabilities‬to‬allow‬both‬the‬
detection‬ and‬ treatment‬ of‬ specific‬ diseases.‬ As described in the 
Main Introduction of this thesis work, nanotechnology may help in 
the transfer of drugs or tracers across the biological barriers to reach 
the target organs in order to treat and/or detect diseases
21,22
. In this 
chapter, the multimodal designed vector (HyCoS) presented in 
chapter one is encapsulated with a dye ATTO680 during the 
coacervation process and consequently functionalized with different 
kinds of selected peptides in order to detect B-cell lymphoma
23
 using 
Fluorescence Microscopy Tomography (FMT). The pA20-36, pA20-
6 and pA20-S are the selected and tested peptides
24
. In 2010, 
Palmieri et al. demonstrated that pA20-36 binds specifically to the 
complementarity-determining regions of the A20 B-cell receptor 
(BCR) and enabling in vivo detection of neoplastic cells (B-cells 
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lymphoma) and at the same time the inhibition of tumor growth in 
vivo
25
. The B-cell lymphomas
26
 is a solid tumor and it is a typical 
lymphoma affecting by B cells. They usually develop more 
frequently in older adults and in immunocompromised individuals. 
Lymphomas require intensive treatments and the patients are kept 
under control with long-term survival of many years. There are 
different kinds of lymphomas involving B cells as diffuse large B-
cell lymphoma, follicular lymphoma, marginal zone B-cell 
lymphoma (MZL) or Mucosa-Associated Tissue lymphoma 
(MALT), small lymphocytic lymphoma (leukemia) and Mantle cell 
lymphoma (MCL) while other rare forms are much less common. 
NPs‬structure‬intended‬for‬the‬carriage‬of‬medications‬is‬complicated‬
because‬ the‬ effectiveness‬ in‬ achieving‬ the‬ target‬ site‬ depends‬ on‬
many‬factors.‬Physico-chemical‬properties‬as‬structure,‬density,‬type‬
of‬ligand‬and‬the‬chemistry‬of‬conjugation‬contribute‬strongly‬to‬the‬
effectiveness‬ of‬ the‬ system.‬ The‬ effectiveness‬ of‬ the‬ strategy‬ of‬
active‬targeting‬in‬vitro‬and‬especially‬in‬vivo‬ is‬also‬influenced‬by‬
other‬ factors‬ such‬ as‬ the‬ route‬ of‬ administration‬ and‬ non-specific‬
protein‬binding‬as‬they‬pass‬through‬the‬bloodstream.‬The‬specificity‬
of‬ targeting‬ will‬ be‬ determined‬ by‬ the‬ biodistribution‬ of‬ ligand-
Functionalized‬and‬as‬the‬complex‬NPs‬interacts‬with‬molecules‬off-
target‬ and‬ healthy‬ cells.‬The aim of this work has been to test the 
different peptides combined with the produced HyCoS NPs to study 
their behavior when they are conjugated to our complex nanocarrier 
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to improve the detection power of the peptide thanks to the presence 
of a specific dye which is detectable by FMT without any 
interference with biological tissue. In addition, the MRI properties of 
the nanoparticles have been preserved and combined with these 
optical properties in order to perform perspectively the multimodal 
imaging- The obtained NPs are functionalized with peptides using 
two types of reactions: a direct one and an indirect one. The 
protocols of the reactions are designed to maintain the stability of the 
nanovectors and to reach the right concentration for in vivo 
applications. The resulted probes are administrated to C57 bulb mice 
engrafted with A20 lymphoma using the A20 and 5T33MM cell line 
used by Palmieri et al. for their work
25
. In this case, the NPs are used 
for both diagnostic and therapeutically purposes. In this work, 
peptides on nanoparticles surface may address the nanoparticles to 
the tumor area 
27
. In fact, active targeting, also called ligand-
mediated targeting
28
, uses the affinity of the ligand, exposed on the 
surface of NPs, to molecules or overexpressed receptors in diseased 
organs, tissues, cells or subcellular domains
8
. The design of such 
systems is given then to increase the interactions between NPs and 
cells that the internalization of ligand optimized without altering the 
general biodistribution
26
. 
Such‬ systems‬ should‬ be‬ capable‬ of‬ selectively‬ attack‬ cancer‬ cells,‬
thanks‬to‬the‬modification‬of‬the‬surface‬with‬specific‬ligands‬for‬the‬
tumor29,‬sparing‬the‬healthy‬tissue‬toxic‬effects‬of‬medication‬that‬are‬
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observed‬with‬ conventional‬ therapies.‬The‬ ability‬ to‬ target‬ specific‬
cells‬ could‬ improve‬ the‬ effectiveness‬ of‬ reducing‬ the‬ toxicity30.‬
Selective‬ treatment‬ based‬ on‬ nanoparticles‬ would‬ represent‬ a‬
significant‬improvement‬over‬the‬standard‬drug‬therapy,‬in‬which‬the‬
drug‬can‬be‬ internalized‬by‬virtually‬any‬cell‬with‬possible‬damage‬
to‬normal‬tissues31.‬ 
2.2 Materials 
Materials‬ used‬ for‬ Nanoparticle‬ preparation:‬ Chitosan‬ (Ch)‬ low‬
molecular‬ weight;‬ Sodium‬ Tripolyphosphate‬ (TPP)‬ 367.86‬ g/mol;‬
Glacial‬ Acetic‬ Acid‬ molecular‬ weight‬ 60.05;‬ Ethanol‬ (EtOH)‬
molecular‬ weight‬ 46.07;‬ Gd-DTPA‬ molecular‬ weight‬ 547.57;‬
Mineral‬ Oil‬ 0.84‬ g/mL‬ at‬ 25°C‬ (lit.);‬ Span80‬ molecular‬ weight‬
274.43;‬ 1.005‬ g/mL‬ at‬ 20‬ °C‬ (lit.);‬ ATTO680‬ 652‬ g/mol‬ are‬
purchased‬by‬Sigma-Aldrich‬while‬Hyaluronic‬Acid‬ (HA)‬850‬kDa‬
parenteral‬ grade‬ is‬ by‬ Hyasis.‬ MilliQ‬ water‬ is‬ used‬ for‬ all‬
experiments. 
Reactants‬ used‬ for‬ conjugation‬ of‬ peptide‬ to‬Nanoparticles:‬ REDC‬
(1-ethyl-3-(3-dimethylaminopropyl)‬ carbodiimide‬ hydrochloride),‬
NHS‬ (N-hydroxysuccinimide)‬ and‬ Streptavidin‬ are‬ purchased‬ by‬
Sigma-Aldrich.‬ Peptides‬ A20-6S‬ (ICSPVSCSK;‬ MW:‬ 1067‬ Da),‬
A20-36‬ ((EYVNCDNLVGNCVIRG,‬MW:1922‬Da)‬ and‬A20-6‬ are‬
produced‬by‬Caslo. 
Polystyrene‬NPs‬by‬Thermo‬are‬used‬for‬PEG-FITC‬quantification. 
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Cell‬lines‬are‬the‬A20‬and‬5T33MM‬cell‬lines‬are‬used‬to‬induce‬B-
cell‬lymphoma‬in‬C57‬bulb‬mice‬model9.‬  
VivoTag®‬750-S‬ (Perkin‬Elmer)‬ and‬Dimethyl‬ sulfoxide ‬ (DMSO)‬
by‬Sigma-Aldrich‬are‬used‬for‬the‬preparation‬of‬labeled‬peptide.‬ 
2.3 Methods 
2.3.1 Nanoparticles (NPs) preparation 
The‬Nanoparticles‬(NPs)‬are‬produced‬by‬an‬Emulsion-Coacervation‬
method‬starting‬from‬a‬w/o‬emulsion‬(Chapter‬1‬paragraph‬1.3).‬The‬
starting‬emulsion‬is‬composed‬of‬a‬water‬phase‬of‬1%‬wt/v‬Ch,‬1:1‬
Gd-DTPA,‬ 1mg‬ATTO680‬ in‬ a‬ solution‬ of‬Acetic‬Acid‬ at‬ pH4.5,‬
while‬the‬Oil‬solution‬is‬composed‬of‬1%‬v/v‬Span80‬and‬45‬ml‬of‬
Mineral‬ Oil.‬ The‬ two‬ phases‬ are‬ homogenized‬ for‬ 20‬ minutes‬ at‬
7000rpm,‬ then‬a‬ second‬water‬phase‬containing‬0.1%‬wt/v‬HA‬and‬
30%‬wt/v‬of‬TPP‬is‬added‬dropwise‬to‬the‬previous‬emulsion‬and‬it‬
is‬ homogenized‬ at‬ 7000‬ rpm‬ for‬ further‬ 30‬ min.‬ The‬ obtained‬
emulsion‬is‬stirred‬at‬300‬rpm‬over‬night‬until‬that‬the‬coacervation‬
of‬HA‬occurs.‬Then,‬different‬purification‬steps‬are‬made‬in‬order‬to‬
remove‬the‬oil‬phase‬and‬to‬purify‬the‬obtained‬NPs. 
2.3.2 Preparation of labeled ‬peptide Biotin-
EYVNCDNLVGNCVIRG-VivoTag 750S‬ 
Peptide‬Biotin-EYVNCDNLVGNCVIRG‬lyophilized‬is‬prepared‬by‬
dissolving‬1mg‬in‬1mL‬of‬50‬mM‬carbonate/bicarbonate‬buffer,‬pH‬
8.5,‬with‬a‬concentration‬of‬1mg/mL.‬ 
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One‬ mg‬ of‬ VivoTag®‬ 750-S,‬ a‬ near‬ infrared‬ fluorescent‬ imaging‬
labeling‬ agent‬ containing‬ an‬N-hydroxysuccinimide‬ (NHS)-ester,‬ is‬
reconstituted‬with‬100‬µL‬of‬DMSO‬in‬a‬dark‬vial.‬200‬µL‬of‬peptide‬
solution‬is‬incubated‬with‬20‬µL‬of‬VivoTag®‬750-S‬solution‬for‬one‬
hour‬ without‬ direct‬ exposure‬ to‬ light‬ at‬ room‬ temperature.‬ After‬
incubation,‬ the‬ reaction‬ mix‬ is‬ purified‬ by‬ a‬ size‬ exclusion‬
chromatography‬ Sephadex™‬ G-25‬ Medium‬ PD-10‬ Desalting‬ (GE‬
Healthcare).‬ The‬ elution‬ monitoring‬ and‬ determination‬ of‬ protein‬
concentration‬ are‬ performed‬ spectrophotometrically‬ at‬ 280‬ nm‬ and‬
750‬ nm.‬After‬ the‬ purification,‬ a‬ peptide‬ at‬ a‬ concentration‬ of‬ 0.1‬
mg/mL‬is‬obtained‬and‬a‬fluorophore‬concentration‬of‬169‬µM.‬The‬
solution‬is‬stored‬at‬4‬°C‬in‬a‬dark‬vial. 
2.3.3 General strategies for the conjugation of peptides 
and PEGylation  
The‬obtained‬NPs‬are‬conjugated‬with‬PEG‬and‬different‬peptides.‬In‬
the‬following‬paragraphs,‬the‬conjugation‬protocols‬are‬presented.‬ 
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2.3.3.1 Conjugation of NPs with peptides 
 
 
Figure 2-2: Set of performed reactions: Schematically representation of the two 
types of performed reaction to conjugate the NPs with the selected peptides. 
To‬ have‬ an‬ active‬ targeting,‬ the‬ obtained‬NPs‬ are‬ conjugated‬with‬
peptides‬ A-20-6,‬ A-20-36,‬ A-20-S‬ using‬ two‬ different‬ strategies‬
called‬ direct and indirect conjugation‬ (Figure‬ 2-‬ 2).‬ The‬ different‬
peptides‬differ‬from‬each‬other‬for‬the‬terminal‬aminoacid.‬ 
Carbodiimide‬chemistry‬is‬used‬for‬bioconjugation‬of‬nanoparticles.‬
Carboxyl‬ groups‬ exposed‬ by‬ an‬ external‬ shell‬ made‬ of‬ HA‬ are‬
covalently‬ bonded‬ to‬ amine‬ group-bearing‬ functional‬ moieties‬
through‬EDC/NHS‬linkers,‬forming‬an‬amide‬linkage.‬In‬the‬case‬of‬
the‬direct‬reaction,‬the‬NPs‬are‬directly‬conjugated‬with‬the‬peptides‬
after‬the‬activation‬by‬EDC/NHS‬of‬the‬carboxylic‬groups.‬ 
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Differently,‬ in‬ the‬ indirect‬ strategy,‬ the‬Carboxyl‬groups‬of‬HA‬are‬
activated‬by‬EDC/NHS‬and‬the‬streptavidin‬covers‬the‬whole‬surface‬
of‬the‬NPs.‬Only‬at‬the‬end,‬the‬peptides‬reacted‬by‬biotin‬covalently.‬
These‬ two‬ strategies‬ are‬ performed‬ in‬ order‬ to‬ study‬ the‬
biodistribution‬of‬the‬conjugated‬NPs‬in‬presence‬and‬in‬absence‬of‬
the‬streptavidin,‬which‬is‬already‬present‬naturally‬in‬the‬body‬and‬so‬
it‬may‬accumulate‬easily‬in‬vivo. 
2.3.3.2 Direct Conjugation Protocol 
250‬µl‬of‬EDC‬and‬250‬µl‬of‬NHS‬are‬added‬to‬500‬µl‬of‬NPs,‬after‬
10‬min‬of‬stirring‬50‬µl‬of‬peptide‬1mg/ml‬(A-20‬S,‬A-20-36,‬A-20-
6)‬are‬added.‬After‬3h‬the‬reaction‬of‬conjugation‬is‬completed.‬After‬
the‬ addition‬ of‬ peptides‬ or‬ the‬ PEG-Cy7,‬ a‬ purification‬ protocol‬
(ultracentrifuge:‬7000rpm,‬4°C,‬15min)‬is‬erquired‬to‬clean‬the‬NPs‬
solutions‬ from‬ the‬ residual‬ reaction‬ components.‬ In‬ addition,‬ after‬
the‬purification‬through‬dialysis,‬the‬NPs‬are‬suspended‬in‬1‬mL‬PBS‬
1ml. 
2.3.3.3 Indirect  Conjugation Protocol 
250‬µl‬of‬EDC‬and‬250‬µl‬of‬NHS‬are‬added‬to‬500‬µl‬of‬NPs.‬After‬
10‬ min,‬ 100‬ µl‬ of‬ Streptavidin‬ (1mg/ml)‬ are‬ added‬ and‬ the‬ final‬
suspension‬ is‬ stirred‬ overnight.‬ After‬ the‬ overnight,‬ the‬ NPs‬ are‬
separated‬ by‬ the‬ residual‬ of‬ Streptavidin‬ using‬ an‬ Ultracentrifuge‬
(Conditions:‬20‬min,‬4°C,‬7000‬rpm).‬Then,‬50‬µl‬of‬peptide‬1mg/ml‬
are‬added‬to‬the‬suspension‬of‬NPs‬with‬Streptavidin‬obtained.‬The‬
reaction‬of‬conjugation‬is‬completed‬after‬3h.‬ 
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After‬the‬addition‬of‬peptides,‬it‬is‬required‬a‬purification‬protocol‬to‬
remove‬ the‬ residual‬ reaction‬components‬ from‬ the‬NPs‬ suspension.‬
The‬NPs‬are‬purified‬using‬dialysis‬tubes‬50kDa‬in‬a‬water‬phase.‬In‬
addition,‬ after‬ the‬ purification‬ through‬ dialysis,‬ the‬ NPs‬ are‬
suspended‬in‬PBS‬until‬1ml.‬ 
2.3.3.4 PEGylation 
230‬µl‬of‬EDC‬and‬230‬µl‬of‬NHS‬ are‬ added‬ to‬500‬µl‬of‬NPs‬ in‬
order‬to‬activate‬the‬carboxylic‬groups‬of‬the‬external‬shell‬made‬of‬
HA.‬After‬10‬min‬of‬stirring‬40‬µl‬of‬PEG-FITC‬(1mg/ml)‬are‬added.‬
The‬conjugation‬reaction‬is‬kept‬under‬continuous‬stirring‬overnight. 
2.3.3.5 Cell line growth conditions 
The‬ A20‬ B-cell‬ lymphoma‬ cell‬ line‬ bear‬ surface‬ IgG‬ (sA20-Ig),‬
which‬is‬also‬secreted‬in‬the‬culture‬medium‬(A20-Ig).‬The‬A20‬cells‬
are‬ adapted‬ to‬ growth‬ in‬ serum-free‬ culture‬medium‬ supplemented‬
with‬ 50‬ units/ml‬ penicillin,‬ 50‬ µg/ml‬ streptomycin‬ and‬ 2‬ mM‬ L-
glutamine.‬Culture‬supernatant‬of‬A20‬cell‬produced‬2–10‬µg/ml‬of‬
A20-Ig,‬as‬estimated‬by‬ELISA.‬The‬surface‬IgG-positive‬5T33MM‬
B‬ cell‬ line‬ was‬ grown‬ in‬ RPMI‬ medium,‬ supplemented‬ with‬ 10%‬
fetal‬bovine‬serum,‬50‬units/ml‬penicillin,‬50‬µg/ml‬streptomycin‬and‬
2‬ mM‬ L-glutamine.‬ The‬ A20-Ig‬ was‬ purified‬ from‬ the‬ culture‬
supernatants‬by‬using‬the‬Mab‬Trap™‬antibody‬purification‬Kit‬(GE‬
Healthcare),‬according‬to‬the‬manufacturer’s‬instructions. 
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2.3.4 Physical characterization  
2.3.4.1 Advanced Electron Microscopy  
‬A‬ field‬ emission‬ gun‬ (FEG)‬ scanning‬ electron‬ microscope‬ (SEM)‬
Zeiss®,‬transmission‬electron‬microscope‬(TEM)‬FEI®‬in‬DRY‬and‬
CRYO‬ mode,‬ Confocal‬ Microscope‬ (STED‬ Stimulated‬ Emission‬
Depletion)‬ are‬ used‬ in‬ order‬ to‬ characterize‬ the‬ system‬
morphologically.‬ The‬ SEM‬ characterizations‬ are‬ made‬ after‬ the‬
dialysis‬to‬control‬the‬integrity‬of‬the‬nanostructures‬by‬collecting‬the‬
nanoparticle‬ on‬ an‬ ISOPORE‬ membrane‬ (pore‬ size‬ 100nm.)‬ The‬
sputter‬ coating‬ of‬ the‬ samples‬ is‬ made‬ with‬ 7nm‬ Au.‬ The‬ TEM‬
analyses‬are‬brought‬forward‬both‬in‬DRY‬mode‬and‬Cryo‬Mode.‬In‬
the‬DRY‬mode,‬the‬samples‬are‬prepared‬using‬Formvar/Carbon‬200‬
mesh‬ Cu‬ Agar®‬ using‬ 20µl‬ of‬ the‬ suspended‬ nanoparticles.‬ For‬
CRYO-mode,‬ lacey‬ carbon‬ membranes‬ on‬ 300-mesh‬ copper‬ grids‬
are‬used.‬A‬sample‬of‬the‬diluted‬suspension‬is‬dropped‬on‬the‬grid,‬
blotted‬to‬a‬thin‬film‬with‬filter‬paper,‬and‬immediately‬plunged‬into‬
liquid‬ propane/ethane‬ (-186‬ °C)‬ using‬ a‬ vitrification‬ system‬
(Vitrobot,‬ purchased‬ by‬ FEI). A‬ Gatan‬ model‬ 626‬ cryo-transfer‬
station‬and‬a‬cryo-holder‬are‬used‬to‬transfer‬the‬grid‬containing‬the‬
vitrified‬suspension‬ into‬a‬TEM‬Tecnai‬FEI‬200‬kV.‬Hydrodynamic‬
diameter‬and‬size‬distribution‬of‬the‬nanosystems‬are‬measured‬using‬
a‬ Zetasizer‬ Nano‬ ZS‬ instruments‬ (Malvern‬ Instruments‬ Ltd.,‬
Worcestershire,‬ UK),‬ at‬ an‬ operating‬ wavelength‬ of‬ 532‬ nm.‬
Measurements‬ of‬ size‬ distribution‬ and‬ the‬ Z-average‬ size‬ of‬
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nanoparticles‬are‬performed‬at‬25‬°C‬with‬an‬angle‬detection‬of‬173°‬
in‬optically‬homogeneous‬glass‬cuvettes.‬The‬samples‬are‬taken‬from‬
the‬ suspension.‬ The‬ Zeta‬ potential‬ is‬ used‬ in‬ the‬ same‬ way‬ by‬
determining‬the‬Electrophoretic‬Mobility‬in‬a‬Folded‬Capillary‬Zeta‬
cell.‬Each‬sample‬is‬measured‬five‬times‬and‬average‬serial‬data‬are‬
calculated.‬ Stimulated‬ Emission‬ Depletion‬ (STED)‬ or‬ Confocal‬
Microscopy,‬dependence‬on‬the‬wavelength,‬are‬used‬to‬evaluate‬the‬
fluorescence‬ and‬ stability‬ of‬ the‬ NPs.‬ The‬ samples‬ are‬ prepared‬
drying‬ 20µl‬ of‬ nanoparticles‬ suspension‬ deposited‬ on‬ a‬ FluorDish.‬
Nanoparticles‬are‬diluted‬in‬Ethanol‬or‬in‬Phosphate-Buffered‬Saline‬
(PBS).‬A‬typical‬dilution‬factor‬is‬1:100. 
2.3.5 Quantitative Analysis  
2.3.5.1 PEG Concentration 
The‬ amount‬ of‬ PEG-FITC‬ conjugated‬ to‬ the‬ NPs‬ is‬ calculated‬ by‬
Spectrofluorimetry‬(EnSpire‬Multimode‬Plate‬Reader‬PerkinElmer).‬
Different‬concentrations‬of‬ the‬NPs‬suspension‬are‬investigated‬and‬
compared‬ with‬ a‬ calibration‬ line.‬ Each‬ measurement‬ is‬ made‬ in‬
triplicate.‬ 
2.3.5.2 Bicinchoninic Acid Protein (BCA) Assay 
To‬determine‬ the‬concentration‬of‬ the‬peptide‬on‬ the‬surface‬of‬ the‬
NPs,‬ the‬BCA‬assay‬ (QuantiProTM‬BCA‬assay‬kit,‬Sigma-Aldrich)‬
is‬used.‬This‬Assay‬is‬chosen‬because‬it‬is‬extremely‬precise,‬in‬fact,‬
it‬has‬been‬able‬to‬detect‬an‬amount‬of‬0.5µg/ml.‬The‬bicinchoninic‬
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acid‬ under‬ alkaline‬ conditions‬ is‬ a‬ highly‬ sensitive‬ reagent,‬ stable‬
and‬ specific‬ for‬ the‬ Cu+,‬ and‬ forms‬ with‬ it‬ a‬ compound‬ of‬ the‬
intensity‬ of‬ the‬ purple‬ color‬ that‬ is‬ proportional‬ to‬ the‬ amount‬ of‬
presented‬protein10‬11. 
The‬ variation‬ of‬ the‬ intensity‬ of‬ the‬ signal‬ is‬ determined‬ by‬
absorbance‬spectrophotometer‬measures‬at‬562nm.‬ 
150µl‬ of‬ NPs‬ suspension‬ are‬ added‬ to‬ the‬ same‬ quantity‬ of‬ the‬
working‬reagent‬solution‬and‬the‬obtained‬suspension‬is‬incubated‬at‬
37°C‬ for‬ 2h.‬ The‬ results‬ are‬ compared‬ with‬ a‬ calibration‬ line‬ of‬
Bovine‬ Serum‬ Albumin‬ (BSA)‬ and‬ the‬ concentration‬ value‬ is‬
extrapolated‬by‬a‬calibration‬line‬designing‬by‬using‬BSA‬samples‬at‬
a‬known‬concentration‬ (0-40‬µg/ml).‬All‬ the‬measures‬ are‬made‬ in‬
triplicate.‬ 
2.3.6 Fluorescence Tomography (FMT) Analysis Protocol 
Mice‬ blood‬ clearance,‬ organ‬ distribution‬ and‬ in‬ vivo‬ imaging‬ are‬
investigated‬ with‬ an‬ FMT‬ 4000‬ TM‬ fluorescence‬ system‬
(PerkinElmer,‬Massachusetts‬USA)‬equipped‬with‬four‬channels. 
The‬ FMT‬ analysis‬ are‬ conducted‬ on‬ C57/BULB‬ mice‬ model‬
subjects.‬After‬12‬days‬of‬tumor‬cells‬injections,‬all‬mice‬are‬divided‬
into‬4‬groups‬divided‬ for‬ intravenously‬ injection:‬ the‬ first‬ (n‬=‬12)‬
received‬ 100‬ µL‬ of‬ Vivotag‬ 750S‬ conjugated‬ with‬ peptide,‬ the‬
second‬(n‬=‬12)‬received100‬µL‬of‬Peptide‬A-20-36-NPs,‬the‬third‬(n‬
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=‬12)‬received100‬µL‬of‬Peptide‬A-20-s-NPs,‬the‬fourth‬group‬of‬ctrl‬
mice‬received‬100‬µL‬of‬A-20-36-NPs.‬All‬nanoparticles‬are‬loaded‬
with‬the‬ATTO680‬and‬the‬FMT‬instrument‬is‬adequately‬calibrated.‬
During‬ FMT‬ studies‬ animals‬ are‬ maintained‬ in‬ general‬ anesthesia‬
and‬at‬37‬°C‬body‬temperature.‬Anesthesia‬is‬initially‬delivered‬in‬an‬
induction‬chamber‬saturated‬with‬5%‬isoflurane‬(Iso-Vet‬1000‬mg/g‬
Inhalation‬Vapor,‬Piramal‬Healthcare‬UK‬Ltd.,‬Northumberland,‬UK)‬
in‬ oxygen‬ (2‬ L/min)‬ and‬ subsequently‬ maintained‬ during‬ all‬
procedures‬ with‬ isoflurane‬ (2.5%‬ during‬ FMT‬ examination)‬ in‬
oxygen‬at‬2‬L/min.‬For‬ each‬mouse,‬we‬performed‬a‬basal‬ scan‬of‬
about‬10‬minutes‬ and‬we‬ injected‬100‬μl‬of‬ contrast‬agent‬ into‬ the‬
tail‬vein‬and‬wait‬30‬minutes‬for‬the‬dye‬biodistribution.‬Imaging‬is‬
performed‬at‬1,‬2,‬4,‬6,‬24‬h‬post‬injection,‬which‬collected‬both‬2D‬
surface‬fluorescence‬reflectance‬images‬as‬well‬as‬3D‬FMT‬imaging‬
datasets,‬ we‬ used‬ a‬ proprietary‬ software‬ (TrueQuant‬ 3.1)‬ for‬ the‬
quantitation‬ of‬ three-dimensional‬ fluorescence‬ signal‬ within‬ mice‬
body.‬At‬the‬end‬of‬the‬FMT‬study‬animals‬are‬sacrificed,‬tumors‬are‬
surgically‬ removed,‬ and‬ immediately‬ frozen‬ in‬ liquid‬ nitrogen‬and,‬
for‬ immunohistochemical‬ analysis.‬ A two-dimensional region of 
interest (ROI) is placed on the whole tumor area including about five 
millimeters of neighboring apparently normal tissue, or on the whole 
lower abdomen / pelvic area in the positive control mice, i.e. a 
tumor-bearing mice injected with VivoTag
®
-S 750 (PerkinElmer 
Inc., Waltham, MA, USA) and HyCoS. In each mouse, the ROI is 
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duplicated without changing its dimensions, to reduce this source of 
bias as much as possible. The signal intensity (I) obtained in 
counts/energy at each time point (It) is normalized to the background 
signal (IB) according to the formula: Inorm = (It – IB) / IB * 100. The 
Inorm resulting significantly different between groups are reported as 
mean ± standard error of the mean (SEM). A multivariate analysis of 
variance for repeated measures (RM-MANOVA) is used to study the 
fixed effects of the treatment group (NPs + PEP, NPs + Scrambled 
PEP, VivoTag), of the time and of the interaction of the time over 
groups‬(a‬difference‬in‬the‬“slope”‬of‬the‬curves‬between‬groups).  
The‬imaging‬sessions‬are‬rapid‬(2-3‬minutes‬per‬animal)‬and‬for‬this‬
range‬ of‬ time‬ the‬ mouse‬ remains‬ stable‬ and‬ immobilized‬ for‬
consistent,‬repetitive‬imaging‬results.‬ 
The‬FMT‬investigations‬are‬made‬at‬different‬time‬steps‬in‬order‬to‬
control‬the‬biodistribution‬of‬the‬complex‬peptide-NPs.‬The‬animals‬
are‬monitored‬until‬recumbent.‬ 
2.4 Results 
In this second chapter, the effect of the chemical decoration of the 
HyCoS NPs is studied. Two different conjugation protocols are 
presented in order to functionalize HyCoS NPs with selected 
peptides and PEG. The functionalized NPs are used for optical 
imaging and active targeting to detect B-cell lymphoma in C57 bulb 
mice model. 
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2.4.1 Morphological and Super Resolution characterization  
In Figure 2- 3, the produced NPs, obtained by the emulsion-
coacervation method, are shown. During the process of production of 
the NPs both the dye (ATTO 680) and the MRI contrast agent (Gd-
DTPA) are encapsulated. This peculiarity allows the NPs to be used 
for multimodal diagnostic applications.  
The TEM analysis in Figure 2- 3 A shows a core-shell architecture of 
the obtained NPs shown in SEM image (Figure 2- 3 B) while the 
confocal image (Figure 2- 3 C) shows that the encapsulated dye 
(ATTO680) is presented in the whole NPs without any difference 
between the core and the shell.  
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Figure 2-3: Morphological and Optical characterization of produced NPs. NPs are 
morphologically characterized before the conjugation with PEG and peptides. A) 
TEM characterization of core-shell NPs, B) SEM image of NPs and C) Confocal image 
of NPs in which the encapsulated dye is shown in the whole nanovectors.   
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2.4.2 Direct Conjugation Protocol 
The NPs conjugated using the direct conjugation protocol are 
directly linked to the chains of the HA of the shell after their 
activation using EDC and NHS. In Figure 2- 4, NPs after the 
conjugation using the direct protocol are shown. In particular, the 
NPs conjugated with pA20-6 are shown in Figure 2- 4 A, the NPs 
conjugated with pA20-36 are shown in Figure 2- 4 B while the NPs 
conjugated directly with pA20-s are shown in Figure 2- 4 A.  
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Figure 2-4: SEM images of conjugated NPs using the direct protocol. A) NPs 
conjugated with pA20-6, B) NPs conjugated with pA20-36 and C) NPs conjugated 
with pA20-s. 
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2.4.3 Indirect Conjugation Protocol 
In Figure 2- 5 it is possible to notice that the NPs continue to 
maintain their stability also after the conjugation. By this picture 
both the core and the shell can be clearly distinguished, furthermore, 
it is possible to notice a first layer of streptavidin and a final one of 
the peptide. In detail, in Figure 2- 5, NPs after the conjugation with 
the different peptides using the indirect conjugation reaction are 
shown. In particular, the NPs are conjugated with pA20-6 (Figure 2- 
5 A), with pA20-36 (Figure 2- 5 B) and pA20-s (Figure 2- 5 C). The 
Figure 2- 5 shows that the NPs conjugated with the indirect 
conjugation protocol continue to maintain their stability and are 
completely covered by a layer of streptavidin linking the specific 
peptide. 
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Figure 2-5: TEM images of conjugated NPs using the indirect protocol. A) NPs 
conjugated with pA20-6, B) NPs conjugated with pA20-6 and C) NPs conjugated 
with pA20-s.  
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2.4.4 PEG Conjugation Protocol 
In addition to the conjugation with the peptides, the NPs are 
subjected to a second conjugation with a PEG-FITC 1KDa. In Figure 
2- 6 A is reported a TEM image of PEG-FITC-NPs in which can be 
noticed the presence of chains of PEG-FITC of about 100nm 
arranged all around the NPs. The Figure 2- 6 B shows the NPs at 
confocal microscopy, in particular the image shown confirms the 
presence of a layer of dye which is conjugated with the PEG. In the 
case of fluorescent polystyrene (PS) NPs it has been possible to 
evaluate the simultaneous presence of the two dyes, the one which is 
already present in the polymeric NPs and the conjugated one.  
 
Figure 2-6: NPs conjugated with PEG-FITC 1kDa. A) TEM image of PEG-FITC-NPs 
and B) Confocal Image of PEG-FITC-NPs 488nm. 
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In order to evaluate the correct protocol for the NPs conjugation, the 
–COOH groups presented on the surface of the NPs are evaluated by 
volumetric titration.  
In Figure 2- 7 there is a graphical representation of the equivalence 
point obtained by volumetric titration HCl-NaOH.  
 
Figure 2-7: Volumetric Titration: Representation of the equivalence point obtained 
by volumetric titration HCl-NaOH 
 
The results of the volumetric titration report 4 mol/ml of –COOH 
groups for HyCoS NPs. The amount of PEG-FITC which is 
conjugated to the NPs is evaluated by the spectrofluorimeter using 
polystyrene NPs as model NPs. For the polystyrene NPs (Ex/Em 
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650/680 nm) the range of concentration in which it is possible to 
detect the fluorescence has been evaluated as 1-150 µg/ml. In this 
range, there are no saturation events of the signal and the performed 
experiments made at different dilutions confirm there are no 
shielding effects of the NPs. After the purification steps, and due to 
the analyses to quantify the pegylation and bioconjugation the loss of 
an amount of NPs is confirmed. The initial concentration of NPs is 
1250 µg/ml while that one measured after the reaction is 1077 µg/ml, 
it confirms the 14% w/v of loss of NPs using the calibration line 
reported in Figure 2- 8.  
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Figure 2-8: PS NPs: Calibration Line range 0-150 µg/ml. 
 
The amount of conjugated PEG is measured by comparison of 
different ratios of the suspension dilutions of NPs with a calibration 
line of PEG-Cy-7 (Ex/Em 730-820) in a range of 0-40 nmol/ml 
(Figure 2- 9). The result of this investigation reports 27.8 nmol/ml 
with a final yield of 68.95% w/v.  
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Figure 2-9: PEG Cy-7: Calibration line in the range 0-40 nmol/ml. 
. 
In the case of NPs the spectrofluorimeter analysis is made in the 
range 0-100 nmol/ml (Figure 2- 9). The result of this analyze reports 
a concentration 26.74 nmol/ml with a final yield of 66.85% w/v for 
the HyCoS NPs.  
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Figure 2-10: PEG-FITC 1KDa: Calibration line in the range 0-80 nmol/ml. 
 
In order to determine the concentration of the specific peptide which 
is presented on the surface of the NPs the BCA assay has been used 
(Figure 2- 11). In particular, for the indirect reaction a double 
quantification is performed, the first analysis is made on the sample 
after the conjugation with the streptavidin while the second one on 
the final sample after the conjugation with the peptide.  
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Figure 2-11: BCA Assay: Calibration line Bovine Serum Albumin (BSA) 562 nm. 
 
The results are respectively 47.5 nmol/ml with a yield of 47.5% after 
the conjugation with the streptavidin and 40 nmol/ml with a yield of 
80% after the conjugation with the peptide pA20-36 respect to that 
Polystyrene NPs with 200 nmol/ml and a yield of 66% after the 
streptavidin and 130 nmol/ml with a yield of 65% after the 
conjugation with the same peptide. 
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In the case of direct conjugation, the quantification of the peptide is 
made only on the final sample. The analysis reported 22 nmol/ml 
after the conjugation with the pA20-36 peptide with a yield of 73% 
respect to 135 nmol/ml for PS NPs with a yield of 33%.  
For the reaction of double functionalization, PEG-FITC and peptide, 
both a quantification of PEG-Cy7 by spectrofluorimeter and proteic 
quantification are performed. The results are 2 nmol/ml (yield 25%) 
and 15 nmol/ml (yield 75%).  
2.4.5 pH-triggering behavior 
The obtained NPs have demonstrated a pH triggering behavior; in 
fact they tend to dissolve at pH strong acid while they tend to 
maintain their shape at basic conditions. Thanks to the pH triggering 
in the presence of a tumor mass, which is characterized by acid pH 
conditions, the NPs could swell releasing the cargo of dye and 
contrast agent directly in the tumor mass improving the detection.  
2.4.6 In vivo results 
The in vivo FMT studies are performed at baseline, i.e. prior to the 
i.v. injection of NPs, to obtain the background signal, and hence, 
based on previous results, 1, 2, 4, 6 and 24 hours after the NPs 
injection. The main results of FMT in vivo acquisitions are presented 
In Figure 2- 12 for NPs conjugated with A-20-36 and A-20-s 
peptides using the direct strategy. The NPs conjugated with A-20-36 
peptide is the unique that has shown an accumulation compared to 
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the control peptide A-20-s. The Figure 2- 12 A, B and C represent 
the FMT acquisitions at 0h (basal acquisition), 6 and 24 hours 
respectively after the injection of NPs conjugated with A-20-36, 
while the Figure 2- 12 D, E and F represents the FMT acquisition 
respectively at 0h (basal acquisition), 6 and 24 hours after the 
injection of NPs conjugated with A-20-s. In the basal acquisition 
Figure 2- 12 A and D in the images there is not an intensity profile in 
correspondence of the tumour. Post 6h after the NPs injection, only 
in the Figure 2- 12 B it is possible to notice an accumulation of the 
nanotracers while it is not present in Figure 2- 12 E in which the NPs 
with the control peptide A-20-s are injected. After 24h, Figure 2- 12 
C and F in both the images there is not an accumulation of the probe 
highlighting the clearance of the NPs themselves.   
 
Figure 2-12: In vivo FMT analysis: Results of administration of NPs conjugated with 
A-20-36 (Upper image) and with A20-s (Lower images): Basal FMT acquisition (On 
the left), post 6h FMT acquisition (center) and post 24h FMT acquisition (on the 
right). 
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The graphic in Figure 2- 13 shows an accumulation of VivoTag 680 
conjugated with peptide A-20-36 after 1h from the injection (blue 
line) of 67 pmol. Differently, the NPs conjugated with A-20-s 
peptide present an accumulation in the tumor microenvironment after 
6h from the injection (red line) of 43 pmol. These results are 
obtained by performing a quantitative analysis of the Region of 
Interest by FMT measurements. The clearance profile of the two 
probes is similar, in fact both the tested probes are completely 
expelled from the body after 24h from the administration. The 
designed NPs unlike the only dye conjugated to the peptide remain 
for the same time in the body but have an accumulation peak later. 
 
Figure 2-13: Concentration Profile: Measure of the pmol of NPs conjugated with 
peptide by FMT: A-20-36(red line), A-20-s (green line) and VivoTag conjugated with 
A-20-36 peptide (blue line). 
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The RM-MANOVA highlighted a significant influence of all the 
above-mentioned effects (P=0.001; Figure 2- 14). The post hoc 
analysis identified the following significant differences: at one hour 
post injection, the VivoTag group had a normalized signal intensity 
significantly higher than both the NPs-A-20-36 and NPs-A-20-s 
groups (21.1 ± 3.4 vs. 4.7 ± 1.1 vs. 2.7 ± 1.7 %, respectively; 
P=0.004); at four and six hours, the NPs-A-20-36 had a normalized 
signal intensity significantly higher than both the VivoTag and NPs-
A-20-s groups (four hours: 38.9 ± 6.9 vs. 2.1 ± 0.4 vs. 14.8 ± 3.1, 
respectively; P=0.0005 and P=0.02, respectively – six hours 24.2 ± 
0.4 vs. 1.5 ± 0.3 vs. 8.5 ± 3.5 %, respectively; P=0.0002 and 
P=0.002, respectively). At six hours, a difference between NPs-A-
20-s and VivoTag groups was detected, as well (P=0.047). 
 
Figure 2-14: Graphic representation: Mean normalized intensity of the ROI over 
time (P<0.01). In red, the negative control group; in green, the NPs-A-20-36 group; 
in blue the NPs-A-20-s group. 
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2.4.7 Ex vivo Results 
Based on the in vivo biodistribution, ex vivo fluorescent confocal 
microscopy is performed. Briefly, three mice from each group are 
euthanized under general anesthesia after three hours of 
biodistribution of the injected contrast agent (NPs-A-20-36, NPs-A-
20-s, VivoTag). The tumors are removed from each mouse under a 
dissecting microscope, snap frozen in liquid nitrogen into a 50 ml 
falcon vial, and stored at -80°C until analysis. Five µm slices are 
obtained with a cryostat microtome and stained with 4',6-diamidino-
2-phenylindole (DAPI). The slices are hence studied with the 
opportune excitation/emission wavelengths. The results of the 
fluorescent confocal microscopy confirm the in vivo results (Figure 
2- 15). In particular, the results show an accumulation of NPs –A-20-
36 (Figure 2-15 A and B) higher than what obtained for VivoTag®-S 
750 (Figure 2-15 C). 
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Figure 2-15: Ex vivo: Confocal fluorescent microscopy of tumors stained with DAPI 
after three hours of biodistribution. In A and B: two different mice injected with 
NPs-A-20-36. In C: mice injected with VivoTag®-S 750. In D: mice injected with NPs-
A-20-s. The images have obtained with the identical settings of background 
thresholding and fluorescence intensity. 
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2.5 Discussion 
The described nanoparticles produced by the coacervation method 
have been shown to maintain their stability, assessed by SEM and 
TEM analysis, even after conjugations.  
Despite the many application advantages in the use of NPs, some 
fundamental problems hamper their distribution such as the uptake 
by the Reticulo-Endothelial System (RES), accompanied by rapid 
expulsion from circulation to the liver, the spleen or the bone marrow 
and the possibility of incurring the formation of non-specific binding 
with the healthy areas or which do not represent the biological target.  
The addition of PEG to the surface (PEGylation) can reduce modify 
the layer at the interface of the nanoparticles and biological barriers, 
increasing the timing of movement and half-life (t½) and enable long 
circulation of more than 50% of the injected NPs. This effect is also 
obtained for a compound eventually entrapped within the probe. In 
this way, it will be possible to control the residual interference of 
NPs with the RES lowering also the potential exposure of healthy 
organs to the drug. 
In addition to the PEGylation, the two conjugation protocols used to 
functionalize NPs with different kinds of peptides are carried out in 
order to evaluate the different biodistribution of the functionalized 
nanoparticles in the presence or not of streptavidin. Streptavidin is in 
fact highly similar with biotin tending to bond more to tissues when 
it is injected into the body. The surface coated with streptavidin is 
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presented as a powerful and universal tool for tying all types of 
biotinylated molecule. For this reason, the conjugated nanoparticles 
using the direct protocol show a significant accumulation than those 
linked to the peptide in a non-specific manner that begins probably to 
stick to all tissues indiscriminately from the time of injection without 
accumulating in the tumor area of interest. Furthermore, due to the 
above described pH-sensitive behavior reported in vivo, it is possible 
that, once NPs reach the tumor environment, characterized by an acid 
pH, they could disintegrate, releasing the dye encapsulated thus 
allowing a better localization of the optical tracer. This peculiar yet 
interesting behavior required further investigations as so the ability 
of the A20 -36 –HyCoS NPS to reduce the tumor growth. 
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2.6 Conclusions 
The obtained NPs can be functionalized and PEGylated without 
altering the stability of the designed nanovector. The resulted probes 
can be used for multimodal imaging applications, in particular their 
use is devoted to the MRI and Optical Imaging for the detection a 
specific disease thanks to the active targeting. Indeed, the NPs 
oppurtunely functionalized have accumulated in the tumor 
microenvironment of a B-cell lymphoma allowing the optical 
detection of the tumor lesion. Currently, the acquisitions of the data 
to evaluate the reduction of the tumor due to the accumulation of the 
HyCos NPs decorated with the peptide and in vivo MRI experiments 
on animal MRI 9.4 Tesla are work in progress.  
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CHAPTER 3 
3 Gd-DTPA-HyCoS NPs (HyCoS) entrapping 
18F-FDG for simultaneous PET/MRI 
acquisitions. 
 
 
Figure 3-1: Graphical Abstract: HyCoS NPs encapsulating 
18
F-FDG and Gd-DTPA for 
PET-MRI applications. 
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3.1 Introduction 
Nowadays, the modalities available for clinical imaging include 
optical imaging, magnetic resonance imaging (MRI)
1
, nuclear 
imaging (Positron Emission Tomography (PET), Single Positron 
Emission Tomography (SPECT), computer tomography (CT), 
ultrasound (US) and dual imaging techniques as PET-CT or PET-
MRI
2, 3
. In particular, the combination of both morphological (CT 
and MRI) and functional (PET and SPECT) methods
4
, are used to 
increase the diagnostic accuracy
5
. These current technologies could 
have a huge impact in the early diagnosis
6
 of different pathologies as 
neurodegeneration diseases
7
 and, therefore, in the clinical 
management of cognitive decline in early-stage. In this context plays 
a key role the PET/MRI
4, 8
. The integrated PET/MRI system was 
born in 1997 
3
 and has substantially transformed in the last years 
allowing the development of a new instrument that can be able to 
acquire the information simultaneously and to combine them in a 
unique high-resolution image
9
. The guarantee of having in a single 
image with a high anatomical detail which provides the information 
on the metabolic processes associated with a disease not only leads 
to save time and money but also gives the opportunity to make an 
early detection
10
 and so to improve the effectiveness of the 
treatments
11
. Moreover, the simultaneous acquisition immediately 
brings to mind the possibility of improving the performance and 
information content of one instrument using the information obtained 
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by the other instrument: the accuracy of the PET might be improved 
by including the MRI information as the structural framework 
underlying the distribution of the PET signal. Reciprocally, the 
strength of PET to provide absolute quantitative information might 
help validate several MRI techniques in vivo
5
. With the combination 
of these two diagnostic techniques is also possible to monitor the 
therapy and to control if the suggested dose is enough for the disease. 
MRI and PET provide complementary anatomic, physiologic, 
metabolic and functional information. At the beginning, the use of 
these two techniques consisted of two sequential acquisitions and 
only after the two images, the PET one and the MRI one, are 
superimposed in a unique image. This type of acquisition has acted 
to different problems such as the effects of partial volume. 
Simultaneous PET/MRI allows for both spatial and temporal 
correlation of the signals, creating opportunities impossible to realize 
using sequentially acquired data
3
. The features of this new 
technology may be particularly appealing to applications in 
neuroscience
12
 and translational neurologic and psychiatric 
research
13
, considering that MRI represents the first-line diagnostic 
imaging modality for numerous indications and that a great number 
of specific PET tracers are available today to assess functional and 
molecular processes
14
. Nowadays, even though there are on sale a lot 
of different contrast agents and radiotracers there is not a single 
probe that can be used for the simultaneous PET/MRI acquisition. 
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Thanks to nanotechnology, the design of new probes that provide to 
the delivery of drugs and to the combination of different molecular 
targeting is possible
15
. In literature, various works of new multimodal 
probes for PET/MRI are presented but they are mainly based on the 
conjugation of a radiotracer to a carrier through a bioconjugation
16
 
and on the use of not completely biocompatible materials. Until now, 
the only way to use this technique is limited to the administration of 
a cocktail of contrast agents or tracers
17
. Lee et all 
18
 in 2008 
presented a study in which Arginine-Glycine-Aspartic (RGD) were 
conjugated to Iron Oxide NPs to develop a PET/MRI probe for the 
detection of tumor integrin αvβ3.  Hwang et al. 
19
 in 2010, presented a 
review in which is reported state of the art about the development of 
new nanoprobe for PET/MRI acquisitions. In 2010, Zhu et al 
20
 
presented a new probe for PET/MRI formed by Mn-doped Fe2O4 
(MnMEIO) with serum albumin (SA) conjugating them with 
124
I. In 
2011, a different probe for the multimodal imaging PET/MRI was 
presented by Uppal et al.
21
, this probe was created combining Gd and 
64
Cu to evaluate fibrin imaging effect on rats. Yang et al 
22
 
demonstrated a drug delivery function for tumor application 
combining a tracer for MRI with a 
64
Cu and a drug (Doxorubicin) 
conjugating them to SPIOs. In 2013, de Rosales 
17
 described the use 
of cocktails of imaging agents and bimodal agents to acquire 
information by PET/MRI technique and he presented a probe 
(SPIONs) conjugated with 
64
Cu. Furthermore, already in 2011, he 
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presented a new probe for PET/MRI applications to demonstrate the 
high potential of bisphosphonates (BP)-iron oxide conjugation using 
99m
Tc-dipicolylamine (DPA)-alendronate for SPECT/PET-MRI 
applications
23
. An important characteristic of the presented literature 
studies is the use of radiopharmaceuticals which have a very high 
half-life and that are not used in the clinical practice for their higher 
radioactive power. In this work, a core-shell polymeric probe which 
can be used as a tracer for integrated PET/MRI applications will be 
presented. Thanks to an active targeting, as showed in Chapter 2 for 
the Optical Imaging,  the NPs could not follow the common 
metabolic pathway of the radiotracer but it would be able to reach the 
district of interest increasing safety for the patient following the 
clearance of nanoparticles
24
. The chosen radiopharmaceutical is 
Fluorodeoxyglucose (F
18
-FDG)
24
, which is the most commonly used 
in clinical practice for different kinds of diseases
25, 26
. This choice has 
been done in order to easily introduce the designed probe in clinical 
practice.  
3.2 Materials 
Chitosan (Ch) low molecular weight; Divinyl Sulfone (DVS) 118.15 
g/mol; Sodium Tripolyphosphate (TPP) 367.86 g/mol; Glacial Acetic 
Acid molecular weight 60.05; Ethanol (EtOH) molecular weight 
46.07; Gd-DTPA molecular weight 547.57; Mineral Oil 0.84 g/mL at 
25°C (lit.); Span80 molecular weight 274.43; 1.005 g/mL at 20 C 
(lit.) are purchased by Sigma-Aldrich® while Hyaluronic Acid (HA) 
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850 kDa parenteral grade is by Hyasis. MilliQ water is for all 
experiments. Fluorodeoxyglucose (F
18
-FDG) (0.014 mg/ml) is 
synthesized and provided by IRCCS SDN of Naples. 
3.3 Methods 
3.3.1 Preparation of HyCoS Nanoparticles and their 
collection 
As previously reported in Chapter‬1‬(paragraph‬1.3), HyCoSNPs are 
produced through a complex coacervation process in order to obtain 
a core-shell architecture (Chapter‬ 1‬ paragraph‬ 1.3). Briefly, the 
HyCoS NPs are composed of a Chitosan core o and a shell of HA. 
First of all, a w/o emulsion is prepared in order to obtain the core 
template. 50 ml of a solution of Mineral Oil at 1% v/v Span80 is 
homogenized at 7000rpm for 5 min. Then, an Acetic Acid 
(CH3COOH) solution (34.93 mM) at 1% w/v Ch and 1% w/v Gd-
DTPA is added to the previous oil solution and homogenized for 
20min at 7000rpm in order to obtain a w/o nanoemulsion. 
Consequently, a water solution at 30% w/v of TPP and 0.1% w/v of 
HA is added to the previous emulsion and homogenized at 7000rpm 
for other 30min. At the end, the emulsion is kept under continuous 
stirring overnight at 300rpm. After that, the coacervation occurs 
HyCoS NPs a purified and collected in water using the same 
protocols detailly described in Chapter I (paragraph‬ 1.3). After the 
purification step of the NPs, a step of concentration is necessary. 50 
ml of NPs suspended in aqueous solution are concentrated in 5 ml by 
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Rotavapor R-215 Buchi (temperature of bath 37°C, 14mbar), 
achieving a concentration ranging from  3 to 5 mg/mL 
3.3.2 Synthesis of 18F-FDG 
One of the most challenging aspects of this experimental part regards 
the synthesis of 
18
F-FDG. The radiotracer has been produced in the 
laboratories of the diagnostic center IRCCS SDN located in Naples. 
First, the 
18
F is produced by a cyclotron, then, through an automated 
system, the 
18
F is transported in radiopharmacy inside the so-called 
Hot Cells where the reaction with the glucose for the formation of 
18
F –FDG takes place. During the experimental campaign a whole 
batch of the just prepared radiotracers has been dedicated to the 
testing of the nanoparticles. 
3.3.3 Absorption of 18F-FDG in HyCoS NPs containing Gd-
DTPA 
The absorption procedure is conducted at the Radiopharmaceutical 
Department inside the Diagnostic Center IRCSS SDN in Naples 
where the laboratories and the equipment are adequate to manage a 
radiotracer in a safe way. Here, 100µl of NPs (T1=300 ± 20ms) are 
added to 100µl of 
18
F-FDG (0.014 mg/ml) at about 60µCi/ml and 
kept under continuous shaking for 10min. This procedure is repeated 
at least four times for at least 4 batches to achieve the minimum 
detectable concentration to perform the PET/MRI test. Later, all the 
batches are collected added into a Concentrator Corning Disk (SPIN-
X UF 30kDa of 20ml by SIGMA) with 1 ml of MILLIQ water and 
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all the system is put under vacuum allowing the separation of the 
residual radiotracer by the HyCoS NPs  
Both the solution of water and the residual 
18
F-FDG and the 
suspension of NPs are then collected in different tubes in order to 
measure their activities.  
The radioactivity and the MRI signal of the Gd-DTPA-NPs absorbed 
18
F-FDG are measured by an integrated PET/MRI Scanner at 3 Tesla 
by Siemens, Germany.The same experiments are made with decayed 
18
F-FDG in order to establish by Mass Spectrometry (Agilent 
Technologies 6530 Accurate-Mass Q-TOF LC/MS) the amount of 
glucose presented into the NPs after the contact and purification 
process.  
3.3.4 Simultaneous PET/MRI Acquisition 
The radioactive HyCoS NPs are collected and together with the 
eluates of the relatives samples, inserted into dedicated phantom 
(NEMA 2012/IEC NEMA IEC Body Phantom) with fillable spheres 
(Figure 3-2) adequate to guarantee the measurement of the PET and 
MRI acquisition. The phantom is placed at the isocenter of the 
PET/MRI field of view to perform simultaneous PET/MRI 
acquistion. The eluates of the related samples are also measured to 
assess the efficacy of the sorption. The radioactivity in Becquerel 
(Bq) and the relaxometric properties in terms of  T1 (ms) are 
simultaneously obtained by the PET/MRI scan. 
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Figure 3-2: Phantom: Ad hoc Phantom utilized to perform PET/MRI acquisition of 
HyCoS NPs by filling the low volume glass burette with a sample at a specific 
concentration. 
3.3.5 In vitro MRI 
Relaxation times are measured on a Bruker Minispec (mq 60) bench-
top‬ relaxometer‬ operating‬ at‬ 60‬ MHz‬ for‬ protons‬ (magnetic‬ ﬁeld‬
strength: 1.41 T). The acquisitions are performed at 37°C, and before 
each measurement, the sample is placed into the NMR probe for 
about 15 min for thermal equilibration. Longitudinal relaxation 
times, T1, are determined by both saturation (SR) and inversion 
recovery (IR) pulse sequences. The relaxation recovery curves are 
ﬁtted‬ using‬ a‬ multi-exponential model. Relaxivity values, r1, are 
calculated from the slope of the regression line of 1/T1 [s
-1
] versus 
concentration [mM] with a least-squares method using Origin Pro 9.1 
SRO software (OriginLab Corporation, USA). 
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3.4 Results 
In the design of a synthesis process that can be integrated in an 
industrial and certificated quality system currently in use in 
radiopharmaceutical laboratories for the development of a new 
multimodal probe, the first endeavor was to try to integrate the 
production process of polymeric NPs with the synthesis process of 
18
F-FDG. Indeed, the starting idea has been to encapsulate glucose 
during the manufacturing process and later to perform in the Hot Cell 
the substitution of the glucose with the 18F directly within the 
nanoparticles. Unfortunately, the synthesis protocol of 
18
F-FDG, 
such as the others radiopharmaceutical tracers, is made at a 
temperature profile not suitable for polymeric materials(104 ºC) 
(Figure 3- 2).  
 
Figure 3-3: Profile of Pressure and Temperature: 
18
F-FDG synthesis. The top profile 
represents the temperature profile of the 
18
F-FDG synthesis process (°𝐶). The 
integration of NPs with the 
18
F-FDG is performed from the minute 19 (signed in 
blue). The bottom profile is the pressure profile of 
18
F-FDG synthesis (MPa). 
Beyond the difficulties related to the stability of the nanoparticles, 
even the quality controls of the products are compromised and our 
aim is to obtain a product as much as possible transferable to the 
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clinical applications. For this reason, the direct production of a 
polymeric NPs in the Hot Cells results not effective and extremely 
expensive. The second strategy we have carried out regards the 
combination of the 
18
F-FDG with the polymeric NPs by absorption 
of the radiotracer. Indeed, after their production, HyCoS NPs are 
subjected to freeze-drying to remove the excess of water before 
keeping in contact the materials as described in the Method Section 
of this chapter. In conclusion, the best conditions of sorption in terms 
of the stability of the NPs and encapsulation efficiency are obtained 
by adding 100µl of a solution 
18
F-FDG, at 0.014 mg/ml and about  
60µCi/ml (t0), to 500µl of NPs, at a concentration of 1 mg/ml and 
loading Gd-DTPA having a relaxation rate of (T1= 300±20ms).  
3.4.1 Evaluation of decay 18F-FDG absorbed by NPs and 
their stability  
In the following Figure (Figure 3- 3), a calibration line of glucose 
(range 0-0.014 mg/ml) used for the evaluation of the concentration of 
decayed 
18
F-FDG (glucose) by Mass Spectroscopy is shown.  
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Figure 3-4: Calibration Line of Glucose: The quantification of the amount of 
decayed 
18
F-FDG presented in the flowthrough and in the NPs is measured 
considering the calibration line of glucose. 
After the contact and the purification protocols, glucose (decayed 
18
F-FDG) concentration of 0.00325 mg/ml is measured on the flow-
through collected at the bottom of the flask. The difference between 
the starting amount of used 
18
F-FDG and what has been found in the 
flowthrough is reported in Table 2. The difference between the 
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Flowthrough (mg/ml) and the initial amount of 
18
F-FDG gives us the 
quantity absorbed into the NPs.  
Table 2: Mass spectrometry (MS): Measures are made on eluate after a purification 
step of the particles. The results show a sorption of about 60% of the FDG after the 
contact of 10 min with the NPs. The stability of NPs is evaluated by SEM. 
 
In the following figure (Figure 3- 4) a SEM image of NPs after the 
contact protocol with 
18
F-FDG is reported, the image shows that the 
NPs maintain their stability after the absorption too.  
 
Figure 3-5: Morphological characterization of nanoparticles by Fe-SEM:. NPs with 
Gd-DTPA after the sorption step performed with FDG decayed at 0.014 mg/ml.  
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3.4.2 In vitro simultaneous PET/MRI acquisition 
The simultaneous acquisition PET/MRI showed an absorption of the 
18
F-FDG by the HyCoS NPs measuring activity in a range between 
1.87 µCi (Figura 3-6 A) and 3.32 µCi (Figura 3-6 B)after about 90 
min from the synthesis of 
18
F-FDG (60 µCi/ml). The analysis of the 
radioactivity performed on the eluates showed an activity of about 
6µCi at the same time point (Figura 3-6 C and D). The time point is 
been chosen in relation to the half-life of the radiotracer of about one 
hour. The co-registration PET/MRI (Figure 3-6) of the signals on the 
samples do not presents interference, enabling the measurements of  
a T1 equal to 300 ms (Figura 3-6– right – A) and 600 ms (Figura 3-
6– right – B) and the PET in a range between 1.87 (Figura 3-6– 
middle – A) and 3.32 µCi (Figura 3-6 middle-B), 90 min after the 
synthesis of 
18
F-FDG (60 µCi/ml). Results clearly show that the 
amount of radiotracers absorbed by the HyCoS NPs is sufficient to 
obtain a Human Administration dosage. The amount of radiotracers 
not absorbed has been also measure to compare the results. 
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Figure 3-6: Simultaneous PET/MRI acquisition: On the left the Hybrid PET/MRI 
scan, in the center the PET acquisition and on the right the MRI one (Inner 
Diameters: 10 mm (A), 13 mm (B), 17 mm(C), 22 mm (D)). 
 
3.5 Discussion 
The proposed protocol could integrated at the downstream of the 
synthesis of 
18
F-FDG. Indeed, the radiotracer can be entrapped into 
the NPs taking advantages by the positive charge of the chitosan core 
which can attract the radiotracer and control its release by sorption. 
Furthermore, using the method described in this chapter, it is 
possible to integrate directly in radiopharmacy the designed 
nanovectors with the radiotracers mantaining their stability and 
making the product available as a ready-to-use compound in the 
clinical practice. The sorption of the radiotracer within the 
nanoparticles may be due mainly to the concentration gradient 
obtained by freeze drying between the external and the internal phase 
but the entrapment of the radiotracer is probably due to the positive 
charge of the chitosan scorekeeping the radiopharmaceutical 
compound (negatively charged) trapped in the polymer mesh. 
Further in vivo study needed will assess the biodistribution of the 
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nanoparticles. Indeed, when the tracers are entrapped within 
nanoparticles they will follow the biodistribution of the 
nanoparticles. Particularly, the radiotracer will not follow the 
traditional metabolic pathway of the glucose but a new one dictated 
by the nanoparticles. The protocol used enables preparing an 
injectable suspension usable for simultaneous acquisitions PET / 
MRI without altering the chemical nature of the molecules as 
approved by the Food and Drug Administration. (FDA). In addition, 
the boosted relaxometric properties of the HyCoS NPs are also 
preserved providing a probe with improved efficacy. Furthermore, it 
is important to point out that the formulation of the HyCoS NPs in 
terms of amount of radiotracer and metal chelates concentration 
respect the administration dosage and the acquisition window 
currently in clinical use. It represents a significant and unique result, 
paving the way to a new class of probes that could add notable 
development to the diagnostic field and to the nanomedicine in 
general. 
3.6 Conclusions 
In conclusion, the obtained NPs already encapsulated with Gd-DTPA 
for MRI are be able to absorb 
18
F-FDG if previously partially dried. 
Future development of this project will be the study of the 
biodistribution of the multimodal nanovectors to evaluate the 
stability of the complex and the difference between the 
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biodistribution of the 
18
F-FDG and of the complex 
18
F-FDG-Gd-
DTPA HyCos NPs.   
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4 Major findings and Future Perspectives 
This work of thesis is divided in 3 main section: in the first chapter is 
presented an innovative complex coacervation process to produce 
Hybrid Core-Shell (HyCoS) NPs, which can used for Optical 
Imaging and MRI applications, therefore, for theranostic and 
multimodal applications. In particular, in this chapter is demonstrated 
that there is an enhancement of the MRI signal in order to possibly 
reduce the administration dosage clinically used for MRI acquisition. 
Furthermore, in the second chapter it is demonstrated that the process 
presented previously is able to obtain stable NPs, which can maintain 
their stability after the conjugation with different kinds of peptides, 
(A-20-36, A-20-6 and A-20-s) and the PEGylation reaction too. In 
addition, two different protocols of conjugation, a direct one, by 
conjugating the peptide to the surface, and an indirect one using as 
intermediate streptavidin-biotin affinity. Both protocols are tested to 
verify the various effectiveness and evaluate the biodistribution of 
the functionalized HyCoS NPs after their injection in an in vivo mice 
model engrafted with cellB lymphoma. The results are considered 
significant only for the peptide A-20-36, and in particular the direct 
reaction has shown a significant accumulation within the tumor mass 
respect to the HyCoS NPs conjugated with the indirect strategy. In 
fact, the HyCoS NPs opportunely functionalized for a specific tumor, 
a B-cell lymphoma, are detected by FMT for optical imaging 
application presenting an accumulation in the tumor 
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microenvironment after 6h from the injection and a clearance at 24h. 
The in vivo results are confirmed by ex vivo analysis, highlighting 
the presence of the functionalized HyCoS NPs with the peptide A-
20-36 conjugated by the direct strategy into the tumor lesion.  
In the third chapter,  the ability of HyCos NPs to become a probe for 
Multimodal PET/MRI imaging is presented and the preparation of 
the nanoparticles is integrated with the production protocol of a 
radiotracer for nuclear magnetic applications (
18
F-FDG). A precise 
protocol is introduced to obtain the absorption of the selected 
radiotracer by the HyCoS NPs for simultaneous PET/MRI 
applications. The HyCoS NPs preserve a boosting of the MRI signal 
and can absorb a detectable dosage of a radiotracer if opportunely 
pre-freeze-dried.  
The in vitro results performed on a PET/MRI Scan have shown that 
the nanovecors improve the relaxometric properties and preserve the 
radioactivity without any chemical modification of the Food and 
Drug Administration Approved molecules. Furthermore, both the 
MRI and the PET signal acquired by co-registration are not 
influenced by the presence of the polymer nanovector and any 
interferences are detected allowing their simultaneous acquisition.  
The future perspectives of this research work are: 
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 Test in vitro and in vivo the biodistribution of the multimodal 
radiotracer-HyCoS NPs to study if exists a difference with 
the distribution of the only radiotracer by simultaneous 
PET/MRI acquisition; 
 Deepen the pH-sensitive behavior of the HyCoS NPs in vitro 
e in vivo 
 Evaluate the reduction of the tumor by using A20-36 peptide 
for the different proposed protocols. 
 Develop a new protocol for the functionalization of the 
PET/MRI nanovector before its integration with the 
radiotracer that does not adversely affect the absorption of 
the radiotracer by the nanovector.  
Study Limitations: 
 Evaluation of the safety profile regarding the ability of 
nanoparticles to improve the stability of the Gd- based 
compounds compared to the clinically approved CAs. 
 Characterization in terms of concentration of the radiotracers 
entrapped in the nanoparticles directly at the downstream the 
hot cell for the production of the 
18
F-FDG. 
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5 Appendix  
5.1 Preliminary Results of Cellular Uptake of 
HyCoS NPs 
In Figure A-1 is presented the uptake by cells of HyCoS NPs. It is 
important to note that most of the NPs incubated with the A549 cells 
are internalized after overnight incubation, as shown in Figure A-1. 
With an incubation time less than 12 hours, the nanoparticles do not 
have the necessary time to cross the membrane in any appreciable 
way, but it is possible to observe a strong interaction between the 
nanoparticles and the A549 at the level of the cell membrane.  
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Figure A-1: Confocal laser scanning microscopy observations of A549 cells 
incubated with nanoparticles loaded with atto633. For each panel, the images from 
left to right show fluorescence of nanoparticles in cells (green), WGA555 
fluorescence in cells (red), cell nuclei stained by DRAQ5 (blue), and the merged one 
of the left four images. All images share the same scale bar. In the last panel is 
possible to observe the fluorescence of the nanoparticles in the cytoplasm following 
an overnight incubation. 
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5.2 ICP-MS Results 
In the following table ICP-MS results are reported for organs (brain, 
liver, spleen, kidneys, heart and lung) of the tested animals. 
Table 3: ICP-MS results reported for brain, liver, spleen, kidneys, heart and lung of 
the 3 tested animals after different administration of HyCoS NPs. (Chapter 1- in vivo 
results). 
Sample  
Gd 158 
(cps) 
gr/L 
Dil 
ratio 
TQ 
Gd-
DTPA 
(P.M.) 
M µM 
T1 
Heart.1 
540,3 
0,00054 100 0,054031 547,57 9,86736E-05 98,67357 
  RSD 1,4%             
T1 
Heart.2 
573,8 
0,000574 100 0,057379 547,57 0,000104789 104,7888 
  RSD 1,4%   100   547,57     
T1 
Heart.3 
544,6 
0,000545 100 0,054456 547,57 9,94503E-05 99,45029 
  RSD 3,0%   100   547,57     
T1 
Lung.1 
553,5 
0,000554 100 0,055353 547,57 0,000101088 101,0876 
  RSD 1,6%   100   547,57     
T1 
Lung.2 
529,9 
0,00053 100 0,05299 547,57 9,67725E-05 96,77249 
  RSD 1,3%   100   547,57     
T1 
Lung.3 
535,4 
0,000535 100 0,053536 547,57 9,77706E-05 97,77059 
  RSD 2,4%   100   547,57     
T1 
Kidneys.1 
1698,9 
0,001699 100 0,169894 547,57 0,000310269 310,2693 
  RSD 2,3%   100   547,57     
T1 
Kidneys.2 
1777,1 
0,001777 100 0,177711 547,57 0,000324545 324,5446 
  RSD 4,0%   100   547,57     
T1 
Kidneys.3 
1603,4 
0,001603 100 0,160342 547,57 0,000292824 292,8243 
  RSD 1,0%   100   547,57     
T1 
Spleen.1 
1650,1 
0,00165 100 0,16501 547,57 0,00030135 301,3502 
  RSD 4,3%   100   547,57     
T1 
Spleen.2 
1761,7 
0,001762 100 0,176172 547,57 0,000321734 321,7338 
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  RSD 8,6%   100   547,57     
T1 
Spleen.3 
1808,5 
0,001808 100 0,180847 547,57 0,000330271 330,2713 
  RSD 3,7%   100   547,57     
T1 
Brain.1 
615,0 
0,000615 100 0,061504 547,57 0,000112321 112,3213 
  RSD 2,1%   100   547,57     
T1 
Brain.2 
650,7 
0,000651 100 0,065072 547,57 0,000118839 118,8386 
  RSD 1,0%   100   547,57     
T1 
Brain.3 
608,2 
0,000608 100 0,060821 547,57 0,000111075 111,0746 
  RSD 0,6%   100   547,57     
T1 Liver.1 2628,5 0,002628 100 0,262847 547,57 0,000480024 480,0245 
  RSD 6,2%   100   547,57     
T1 Liver.2 2570,6 0,002571 100 0,257058 547,57 0,000469453 469,4526 
  RSD 2,4%   100   547,57     
T1 Liver.3 2640,6 0,002641 100 0,264061 547,57 0,000482241 482,2409 
  RSD 1,7%   100   547,57     
T2 
Heart.1 
723,6 
0,000724 100 0,072362 547,57 0,000132151 132,1512 
  RSD 3,9%   100   547,57     
T2 
Heart.2 
766,7 
0,000767 100 0,076674 547,57 0,000140026 140,0257 
  RSD 4,1%   100   547,57     
T2 
Heart.3 
702,1 
0,000702 100 0,070214 547,57 0,000128229 128,2291 
  RSD 1,4%   100   547,57     
T2 
Lung.1 
527,2 
0,000527 100 0,052715 547,57 9,62709E-05 96,27086 
  RSD 0,7%   100   547,57     
T2 
Lung.2 
842,8 
0,000843 100 0,084276 547,57 0,000153909 153,9093 
  RSD 0,3%   100   547,57     
T2 
Lung.3 
605,0 
0,000605 100 0,060504 547,57 0,000110495 110,4948 
  RSD 2,8%   100   547,57     
T2 
Kidneys.1 
736,5 
0,000737 100 0,073654 547,57 0,00013451 134,5098 
  RSD 3,4%   100   547,57     
T2 
Kidneys.2 
801,0 
0,000801 100 0,080097 547,57 0,000146277 146,2767 
  RSD 4,3%   100   547,57     
T2 
Kidneys.3 
748,9 
0,000749 100 0,074888 547,57 0,000136765 136,7651 
  RSD 2,2%   100   547,57     
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T2 
Spleen.1 
1949,3 
0,001949 100 0,194931 547,57 0,000355992 355,9921 
  RSD 2,7%   100   547,57     
T2 
Spleen.2 
1799,3 
0,001799 100 0,179931 547,57 0,000328598 328,5984 
  RSD 3,1%   100   547,57     
T2 
Spleen.3 
1930,3 
0,00193 100 0,193028 547,57 0,000352518 352,5175 
  RSD 0,6%   100   547,57     
T2 
Brain.1 
514,8 
0,000515 100 0,051485 547,57 9,40241E-05 94,0241 
  RSD 3,9%   100   547,57     
T2 
Brain.2 
523,0 
0,000523 100 0,052305 547,57 9,55212E-05 95,52125 
  RSD 3,8%   100   547,57     
T2 
Brain.3 
521,0 
0,000521 100 0,052103 547,57 9,51526E-05 95,15258 
  RSD 0,5%   100   547,57     
T2 Liver.1 2019,8 0,00202 100 0,201976 547,57 0,000368858 368,8583 
  RSD 5,7%   100   547,57     
T2 Liver.2 2190,4 0,00219 100 0,219037 547,57 0,000400017 400,0167 
  RSD 0,9%   100   547,57     
T2 Liver.3 2197,7 0,002198 100 0,219775 547,57 0,000401364 401,364 
  RSD 3,4%   100   547,57     
T3 
Heart.1 
533,6 
0,000534 100 0,053358 547,57 9,74443E-05 97,44428 
  RSD 3,6%   100   547,57     
T3 
Heart.2 
520,8 
0,000521 100 0,05208 547,57 9,51106E-05 95,1106 
  RSD 2,7%   100   547,57     
T3 
Heart.3 
537,4 
0,000537 100 0,053737 547,57 9,81379E-05 98,13792 
  RSD 1,2%   100   547,57     
T3 
Lung.1 
536,7 
0,000537 100 0,053673 547,57 9,80209E-05 98,02089 
  RSD 4,1%   100   547,57     
T3 
Lung.2 
577,4 
0,000577 100 0,057742 547,57 0,000105451 105,4508 
  RSD 1,7%   100   547,57     
T3 
Lung.3 
520,5 
0,00052 100 0,052046 547,57 9,50498E-05 95,04979 
  RSD 3,2%   100   547,57     
T3 
Kidneys.1 
691,5 
0,000692 100 0,069153 547,57 0,00012629 126,2899 
  RSD 2,6%   100   547,57     
T3 778,3 0,000778 100 0,077833 547,57 0,000142143 142,1432 
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Kidneys.2 
  RSD 2,4%   100   547,57     
T3 
Kidneys.3 
986,0 
0,000986 100 0,098597 547,57 0,000180063 180,0633 
  RSD 0,3%   100   547,57     
T3 
Spleen.1 
1354,5 
0,001354 100 0,135446 547,57 0,000247358 247,3577 
  RSD 5,5%   100   547,57     
T3 
Spleen.2 
1497,6 
0,001498 100 0,149756 547,57 0,000273491 273,4913 
  RSD 5,3%   100   547,57     
T3 
Spleen.3 
24,3 
2,43E-05 100 0,002427 547,57 4,43231E-06 4,432313 
  RSD 159,9%   100   547,57     
T3 Liver.1 2096,3 0,002096 100 0,209634 547,57 0,000382845 382,8449 
  RSD 1,6%   100   547,57     
T3 Liver.2 2151,3 0,002151 100 0,215131 547,57 0,000392883 392,8827 
  RSD 0,7%   100   547,57     
T3 Liver.3 2151,3 0,002151 100 0,215131 547,57 0,000392883 392,8827 
  RSD 0,7%   100   547,57     
T3 
Brain.1 
474,6 
0,000475 100 0,04746 547,57 8,66733E-05 86,67333 
  RSD 3,4%   100   547,57     
T3 
Brain.2 
523,2 
0,000523 100 0,052321 547,57 9,55517E-05 95,55168 
  RSD 2,2%   100   547,57     
T3 
Brain.3 
532,8 
0,000533 100 0,053279 547,57 9,73012E-05 97,30118 
  RSD 8,1%   100   547,57     
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List of Abbreviations 
 
NAME ABBREVIATION 
Chitosan  Ch 
Hyaluronic Acid  HA 
Positron Emission Tomography  PET 
Magnetic Resonance Imaging  MRI 
Hybrid Core Shell  HyCoS 
Nanoparticles  NPs 
Fluorescence molecular tomographic FMT 
Radiofrequency  RF 
Computer Tomography  CT 
Ultrasound  US 
Divinyl Sulfone  DVS 
Sodium Tripolyphosphate  TPP 
Contrast Agents  CAs 
two-photon fluorescence  TPF 
Stimulated Emission Depletion  STED 
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Scanning Electron Microscope  SEM 
Transmission‬electron‬microscope  TEM 
Central Nervous System  CNS 
Near-infrared fluorescent  NIRF 
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Collaborations 
- IRCCS SDN Gianturco Street, 113 -80143-Naples.  
SDN, Diagnostics and Nuclear Research Institute, is an integrated 
group of specialist clinics in the diagnostic laboratory and imaging. 
In vivo MRI analysis are performed in the Diagnostic Center. 
Futhermore, the absorption procedure of radiotracer and its 
synthesis are conducted at the Radiopharmaceutical Department 
inside the Diagnostic Center IRCSS SDN in Naples where the 
laboratories and the equipment are adequate to manage a radiotracer 
in a safe way. 
- Ceinge-Biotecnologie Avanzate s.c.a.r.l. Comunale Margherita, 
484-538, 80131 Naples. 
CEINGE - Advanced Biotechnology is a nonprofit consortium that 
deals with advanced biotechnology and its possible applications. 
In vivo FMT measures are conducted in Ceinge Biotecnologie 
Avanzate s.c.a.r.l.. 
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Poster 
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Presentation 
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Other Activities 
- TEAM LEADER during the StartCup Campania with the 
project‬ “KYME”, Regione Campania, Naples. (October 
2016) 
 
 
- Award at the StartCup‬Campania‬with‬the‬project‬“KYME”, 
Regione Campania, Naples. (October 2016) – First classified 
in the Bio& Nano Category. 
 
 
 
KYME is a spin-off project of the “Center for Advanced 
Biomaterials for Healthcare” of Istituto Italiano di 
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Tecnologia (IIT) of Naples in collaboration with the 
University of Naples “Federico II”.   
The project aims to produce injectable medical devices for 
Magnetic Resonance Imaging (MRI). Through the use of 
nanotechnology, KYME aims to improve clinically used 
Contrast Agents (CAs) and to ensure a more effective early 
diagnosis, thus contributing to the improvement of 
diagnostic Imaging. 
 
- Team Leader for the KYME spin-off project at Premio 
Nazionale Innovazione PNI. Modena, Italy (November 
2016) 
 
- Attendance at Bioupper Startup Accelerator, Milan, Italy  
o First selection (21 June – 16 October 2016) 
o Training Week (12-17 December 2016) 
o Acceleration Program (26 January – 6 April 2017) 
o Award Ceremony (12 April 2017) 
 
- Research activity is part of "CeSMeMo - PONa3_00173”.‬
Project aims at the development of biomedical products, in 
particular of novel nanosystems for diagnostics and therapy. 
(June 2014 – December 2016) 
 
- Elevator‬ pitch‬ to‬ event‬ “Unione‬ Centenario‬ Industriali”.‬
(February 2017). 
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Public Links to media reporting about KYME:  
http://openinnovation.startupitalia.eu/55278-20170311-
bioupper-kyme-esami-meno-tossici-piu-dettagliati 
 
http://mobile.ilsole24ore.com/solemobile/main/art/impresa
-e-territori/2017-02-27/digitale-campania-rincorre-
223212.shtml?uuid=AESyJSe 
 
http://www.ilmattino.it/innovazione/biotecnologie/biouppe
r_team_campano_kyme_migliori_idee_business_nanotecno
logia_diagnostica_medica-2279797.html 
 
http://www.rainews.it/dl/rainews/TGR/basic/PublishingBlo
ck-d2203e2e-1690-4898-839d-f712cdab8eb1.html 
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